<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>Magyar Onkologia via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Magyar Onkologia' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Magyar+Onkologia&t=Magyar+Onkologia&s=Search&f=source]]></link>
        <lastBuildDate>Fri, 30 Dec 2011 21:11:10 +0100</lastBuildDate>
        <item>
            <title>[Menopausal symptoms and their treatment emerging during hormonal therapy of breast cancer].</title>
            <link>http://www.medworm.com/index.php?rid=5459101&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22128306%26dopt%3DAbstract</link>
            <description>Authors: Rubovszky G, Horváth Z
    Abstract
    Hormonal compounds play an important role in the treatment of breast cancer. Their side effects may lead to suspension of therapy and consequently to the failure of the expected effect. Common and the same way most prevalent side effects of hormonal compounds are the menopausal complaints which can alter quality of life significantly. The early recognition and treatment of menopausal complaints and symptoms help to reach therapeutic success. In general, of menopausal related complaints the role of hot flash, atrophic vaginitis and sexual dysfunction is emphasized. Within the topic, it is possible to mention some musculo-skeletal complaints according to their similar etiology, the failure of estrogen effect. In the treatment of hot flash non...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5459101</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5459101</guid>        </item>
        <item>
            <title>[Detection of multiple colon and rectal tumors during diagnostic treatment and follow-up].</title>
            <link>http://www.medworm.com/index.php?rid=5459100&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22128307%26dopt%3DAbstract</link>
            <description>Authors: Pikó B, Rahóty P, Krémer I, Zsilák J, Török E, Bassam A, Csiffári M, Dimák S, Kis A, Rus-Gal P, Szabó Z, Veréb B, Puskásné Szatmári K
    Abstract
    Recognition of the commonly encountered colorectal cancer (CRC) generally begins and takes place because of and based on symptoms and signs, due to the unsettled screening of this type of cancer. Sometimes, because of advanced stage cancer urgent surgical intervention could become necessary and, if this is the case, there is no time and possibility for searching for an eventual second tumor and perhaps the patient's status does not permit performing intraoperative investigations either. The incidence of multiple colon cancer is considered to be between 2.5 and 30% according to the literature. That is why one should excl...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5459100</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5459100</guid>        </item>
        <item>
            <title>[The place of skin-sparing mastectomy in oncoplastic breast surgery].</title>
            <link>http://www.medworm.com/index.php?rid=5459099&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22128308%26dopt%3DAbstract</link>
            <description>Authors: Mátrai Z, Gulyás G, Tóth L, Sávolt A, Kunos C, Pesthy P, Bartal A, Kásler M
    Abstract
    Despite its ever increasing popularity, there is no evidence-based confirmation so far on the results of skin-sparing mastectomy, introduced 20 years ago. However, the results of countless published retrospective, long-term trials seem to underpin the ability of the precisely implemeted procedure in early stage invasive and in situ breast cancers to yield the oncological results of modified radical mastectomy. As a result of the procedure involving special surgical techniques, the skin not affected by cancer can be preserved, which facilitates immediate reconstruction and improves cosmetic outcome. The effect of postmastectomy radiotherapy on the reconstruction needs to be considered ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5459099</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5459099</guid>        </item>
        <item>
            <title>[A double immunochemical method for the detection of faecal haemoglobin rectal screening: sensitivity and specificity].</title>
            <link>http://www.medworm.com/index.php?rid=5459098&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22128309%26dopt%3DAbstract</link>
            <description>In this study we compared the sensitivity and specificity of the double immunochemical FECA test for the haemoglobin + albumin content of the faeces with those of control colonoscopy in the detection of colorectal neoplasms. In a 3-year period 154 patients (69 males and 85 females) were scheduled for colonoscopy with previously collected stool samples. The sensitivity and specificity of the double immunochemical test for faecal haemoglobin + albumin content were determined in colorectal neoplasms of different severity. Colonoscopy served as a control examination. Colonoscopy identified in 77 cases benign lesions, and in 10 cases malignant tumours. The double immunochemical test for faecal blood and protein successfully used in model screening population showed in our present study 52.7% se...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5459098</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5459098</guid>        </item>
        <item>
            <title>[Application of PET/CT in the radiotherapy of patients with non-small cell lung cancer].</title>
            <link>http://www.medworm.com/index.php?rid=5459097&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22128310%26dopt%3DAbstract</link>
            <description>Authors: Lõcsei Z, Hideghéty K, Farkas R, Bellyei S, Sárosi V, Sebestyén K, Sebestyén Z, Kovács P, Mangel L
    Abstract
    The goal of this paper was to investigate the influence of FDG-PET/CT scan on the modification of staging and irradiation planning in patients suffering from non-small cell lung cancer (NSCLC). Fifteen patients suffering from NSCLC were analyzed by the authors from January, 2008 to July, 2009. The aim of the analysis was to examine the influence of FDG-PET/CT on irradiation planning and on decision-making of the complex oncologic therapy. The FDG-PET/CT scan was carried out in the position of irradiation performed later. For irradiation planning, planning target volumes (PTV) and the organs of risk were contoured on the patients' topometric CT slides as well as...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5459097</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5459097</guid>        </item>
        <item>
            <title>[The effect of different patient positions on overlapping volumes at the radiotherapy of high-risk prostate cancer patients].</title>
            <link>http://www.medworm.com/index.php?rid=5459096&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22128311%26dopt%3DAbstract</link>
            <description>Authors: Czigner K, Agoston P, Forgács G, Kásler M
    Abstract
    The purpose of the study was to evaluate the relationship among planning target volumes (PTVs) and organs at risk (OARs) based on four different radiotherapy treatment plans for high-risk prostate cancer patients. CT scans were obtained in supine position with knee and ankle support (KAS) and in prone position with belly-board (BB) both with full bladder (FB) and empty bladder (EB). Overlapping volumes of the delineated PTVs and OARs on four different setup combinations (KAS-FB; BB-FB; KAS-EB; BB-EB) were analyzed according to the patient position, bladder filling and circumference of abdomen (CA). Overlapping (∩) was significantly smaller with FB than with EB at the bowels and bladder: PTVpel∩bladder: p=0.0069, PTVp...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5459096</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5459096</guid>        </item>
        <item>
            <title>[mTOR complexes - molecular spiders in molecular networks].</title>
            <link>http://www.medworm.com/index.php?rid=5459095&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22128312%26dopt%3DAbstract</link>
            <description>Authors: Kopper L, Tímár J
    Abstract
    PI3K route is one of the most outstanding signal transduction pathways, which has a key role in the decision-making processes and functions of a cell. In this network mTOR (mammalian target of rapamycin) is a well-known integrator. mTOR forms two complexes, and their increased activity is present in many human tumors. Therefore, mTOR inhibitors became more and more important in the targeted therapy, first of all in the treatment of renal cancer, neuroendocrine pancreatic cancer and certain astrocytomas, and many trials are going on in other tumor types. The therapeutic results are obvious, but problems also occur, which stimulate application of new strategies and development of new drugs in order to approach the more individual cancer therapy.
...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5459095</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5459095</guid>        </item>
        <item>
            <title>[Awareness of family physicians in the oncology care. Screening and diagnosis in the primary care].</title>
            <link>http://www.medworm.com/index.php?rid=5459094&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22128313%26dopt%3DAbstract</link>
            <description>Authors: Bardi J, Kovács E, Rurik I
    Abstract
    Delay time between the first experienced symptoms, visiting doctor and setting diagnosis up may depend on several factors. One hundred and ten cancer patients were compared regarding gender, age, social status, qualifications, economic status, participation in organized screening programs, regular attendance by family physicians and delay in the diagnostic procedures. According to the results, 67% of the patients visited the doctor only in case of symptoms occurring. After recognizing the first symptoms, 44% of the men and 53% of the women turned to doctor within one month. The longest delay time was observed in the case of patients over 60 and some patients with university degree, while usually shorter periods were reported in the case...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5459094</comments>
            <pubDate>Tue, 01 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5459094</guid>        </item>
        <item>
            <title>[Treatment and prevention of infections in cancer patients with neutropenia].</title>
            <link>http://www.medworm.com/index.php?rid=5234513&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21918740%26dopt%3DAbstract</link>
            <description>Authors: Sinkó J
    Abstract
    Prognosis of malignant diseases is significantly influenced by infectious morbidity and mortality. Thus, up to date management of cancer patients, in addition to other supportive care modalities, should also incorporate diagnostic methods and therapy of infections. In order to improve outcome, patients developing febrile neutropenia following antitumour treatment should be adequately informed regarding the risk of infections. At the same time, centres responsible for cancer patient care should set up written protocols for basic workup and empirical antibiotic therapy. Here general characteristics of neutropenic infections developing in solid tumour patients are outlined and key points for risk assessment are highlighted. In addition, options and limits of...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5234513</comments>
            <pubDate>Thu, 01 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5234513</guid>        </item>
        <item>
            <title>[Thoughts about thromboembolic events prophylaxis in cancer patients].</title>
            <link>http://www.medworm.com/index.php?rid=5234511&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21918741%26dopt%3DAbstract</link>
            <description>Authors: Pikó B, Bassam A, Dimák S, Kis A, Csiffári M, Rus-Gal P, Szabó Z, Veréb B
    Abstract
    The risk of venous thromboembolic events (VTE) in cancer patients is higher than in the general population. Treatment may also increase this risk in these patients. Based on the appropriate criteria (of which the most important are the current ministerial guidelines) thrombosis prophylaxis should be started (given that there is no contraindication) on these patients and be continued while they are at risk. In the event of permanent risk thrombosis prophylaxis should be given lifelong. The drug of choice is low-molecular-weight heparin (LMWH) which is safer and more effective than the oral vitamin K antagonists. Platelet aggregation inhibitors have proved unsuccessful in this patient gro...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5234511</comments>
            <pubDate>Thu, 01 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5234511</guid>        </item>
        <item>
            <title>[Permanent implant brachytherapy for early, organ confined prostate cancer. Implementation and initial experience in Hungary].</title>
            <link>http://www.medworm.com/index.php?rid=5234510&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21918742%26dopt%3DAbstract</link>
            <description>Conclusion: This is a report of the first application of PPI in Hungary. The observed rate of acute proctitis was negligible, the rate and severity of acute cysto-prostatitis was tolerable. With the use of intraoperative planning, dose distributions met the dose-volume constraints in most of the cases. The biochemical control is excellent but the follow-up time is still short.
    PMID: 21918742 [PubMed - in process] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5234510</comments>
            <pubDate>Thu, 01 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5234510</guid>        </item>
        <item>
            <title>[18F-FDG PET/CT in lymphomas: difficulties in the evaluation of metabolism due to illness characteristics, and review of literature data].</title>
            <link>http://www.medworm.com/index.php?rid=5234509&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21918743%26dopt%3DAbstract</link>
            <description>Authors: Garai I, Borbély K, Barna S, Szûcs B, Hascsi Z, Tóth Z, Illés A
    Abstract
    Fluor-18-deoxy-glucose (18F-FDG or FDG) positron emission tomography - computer tomography (PET/CT) has recently become integrated into the clinical routine of patients with lymphoma in Hungary. The basic condition of risk-adapted treatment of these patients is the exact staging and early objective evaluation of the effectiveness of therapy. Between 1 May 2007 and 31 October 2010, 1862 18F-FDG PET/CT examinations were conducted for lymphoma patients at the PET/CT Center in Debrecen. This is more than 15% of the total examined patient population, and this rate shows a slight increase with each year. Based on the experience obtained from lymphoma patients by routine metabolic PET/CT scans we analyze...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5234509</comments>
            <pubDate>Thu, 01 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5234509</guid>        </item>
        <item>
            <title>[Modern 3D conformal craniospinal radiotherapy planning method].</title>
            <link>http://www.medworm.com/index.php?rid=5234508&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21918744%26dopt%3DAbstract</link>
            <description>Authors: Sebestyén Z, Kovács P, Gulybán A, Farkas R, Bellyei S, Szigeti A, Gallainé DF, Mangel L
    Abstract
    The main problem of craniospinal irradiation (CSI) is the matching of the fields. The use of a suitable technique is very important because matching of the fields is necessary to use for the optimal cancer irradiation of the long planning target volume (PTV). Since 2007, 8 patients have received CT-based, 3D-planned conformal CSI in our Institute. Patient immobilization was made in prone position in a vacuum bed, using skull and pelvis masks. Organ-at-risk (OAR) contours were made by radiographers. PTV was contoured by radiation oncologists. The prescribed dose to the PTV was 36 Gy with 1.8 Gy dose per fraction. In the planning process the following aspects were taken under...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5234508</comments>
            <pubDate>Thu, 01 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5234508</guid>        </item>
        <item>
            <title>[Those who have survived the illness - Quality of life of Hungarian cancer patients. A retrospective study].</title>
            <link>http://www.medworm.com/index.php?rid=5234507&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21918745%26dopt%3DAbstract</link>
            <description>Conclusions: Quality of life of the respondents 4-9 years after treatment seemed to be adequate as perceived by the participants who showed low level of depression and anxiety. The illness itself has brought positive changes for the participants in their attitudes towards life and their surroundings. In spite of this fact, the perceived threat of the recurrence of cancer remains constant in their everyday life.
    PMID: 21918745 [PubMed - in process] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5234507</comments>
            <pubDate>Thu, 01 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5234507</guid>        </item>
        <item>
            <title>[Investigation of fatty acid profile for diagnostic purposes in mouse melanoma].</title>
            <link>http://www.medworm.com/index.php?rid=5234506&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21918746%26dopt%3DAbstract</link>
            <description>Authors: Telekes A, Rásó E, Vékey K
    Abstract
    The aim of this study was to investigate whether fatty acid profile is a suitable marker for diagnostic purposes in mouse melanoma. Twelve C57Bl/6 male mice were implanted with B16 mouse melanoma cells (106 cells/animal) orthotopically (subcutaneously). After the implantation 4-4 animals were bled by cardiac puncture following narcosis, at days 7, 14, and 21. In order to investigate fatty acid profiles a method based on extraction and HPLC-MS was developed. Signal intensities of 14 fatty acids were determined by mass spectrometry in tumor-free animals as well as tumor bearing animals at the three time points. Mathematical analysis showed non-significant profile changes when control (tumor-free) animals were compared to tumor-implanted...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5234506</comments>
            <pubDate>Thu, 01 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5234506</guid>        </item>
        <item>
            <title>[The emotions of oncologists].</title>
            <link>http://www.medworm.com/index.php?rid=5234505&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21918747%26dopt%3DAbstract</link>
            <description>Authors: Lazányi K, Molnár P, Bugán A, Kiss C, Szántó J, Gonda A, Tóth Z, Hernádi Z, Hadijev J, Remenyik E, Damjanovich L, Dinya T, Flaskó T, Bágyi P, Szluha K
    Abstract
    Emotions are parts of organizational reality to an ever increasing extent. Importantly, they are not just tools in the hand of healthcare workers to achieve better physician / healthcare professional-to-patient interactions but intrinsic processes and characteristics with psychic, cognitive and somatic actions. For a thorough investigation of the issue, a PANAS-X questionnaire was used to examine the emotions of 187 physicians and other healthcare professionals, all engaged in oncology, in 2009. The research succeeded in exploring the overall emotional state oncology professionals had assumed in relation wi...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5234505</comments>
            <pubDate>Thu, 01 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5234505</guid>        </item>
        <item>
            <title>[Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer.]</title>
            <link>http://www.medworm.com/index.php?rid=4922081&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21655472%26dopt%3DAbstract</link>
            <description>Authors: Mátrai Z, Tóth L, Polgár C, Láng I, Gõdény M, Sinkovics I, Horváth Z, Bidlek M, Udvarhelyi N, Bartal A, Sávolt A, Ujhelyi M, Kásler M
    The indication of neoadjuvant chemotherapy has been recently extended; it is now applied not only in locally advanced breast cancer but in primarily resecable tumours as well, in order to promote breast conservation. Based on recent clinical results, the reconsideration of traditional lymph node dissection in axillary staging is timely in patients receiving neoadjuvant chemotherapy. Precise axillary staging needs surgical removal of lymph nodes. Based on prospective randomised trials, sentinel lymph node biopsy appears to be appropriate for axillary staging even in tumours requiring neoadjuvant treatment. The extended indication of sent...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4922081</comments>
            <pubDate>Tue, 07 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4922081</guid>        </item>
        <item>
            <title>[Conformal stereotactic radiosurgery treatment: plan evaluation methods and results.]</title>
            <link>http://www.medworm.com/index.php?rid=4922080&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21655473%26dopt%3DAbstract</link>
            <description>Authors: Kovács P, Sebestyén Z, Farkas R, Bellyei S, Szigeti A, Gulybán A, Horváth Z, Dóczi T, Mangel L
    The purpose of our study was the objective evaluation of micro-multileaf collimator (mMLC)-based stereotactic radiosurgery treatment plans. Forty-seven patients, 71 lesions received static beam conformal stereotactic radiosurgery treatment in our institute between November 2005 and June 2008. Target volume and organs at risk were outlined on a MRI-CT image fusion basis. BrainSCAN 5.31 system (BrainLAB AG, Heimstetten, Germany) was used for treatment planning, Elekta Presice TS linear accelerator (Elekta Oncology Systems Ltd, Crawley, UK) and BrainLAB m3 mMLC were used for treatment delivery. An invasive head frame, mounted to the treatment table, was used with four screws for pa...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4922080</comments>
            <pubDate>Tue, 07 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4922080</guid>        </item>
        <item>
            <title>[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy.]</title>
            <link>http://www.medworm.com/index.php?rid=4922079&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21655474%26dopt%3DAbstract</link>
            <description>Authors: Bartal A, Mátrai Z, Szûcs A, Liszkay G
    Hand-foot syndrome is a highly unpleasant adverse reaction caused by treatment protocols containing capecitabine (an orally administered drug), docetaxel, liposomal doxorubicin infusions or continuously infused 5-fluorouracil. It affects the skin of the palms and soles manifesting characteristic symptoms like erythema, inflammation, dysesthesia, pain, thickening, desquamation and cracking of the skin that may progress to cause wounds and ulceration, negatively influencing quality of life, psychological state and belief in recovery, which often result in the need of permanent or temporary interruption of the oncologic treatment and are potential sources of danger to the completion of the therapy. Adequate provision of the syndrome is of ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4922079</comments>
            <pubDate>Tue, 07 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4922079</guid>        </item>
        <item>
            <title>[Effect of KRAS mutation status on the efficiency of Avastin therapy of colorectal cancer.]</title>
            <link>http://www.medworm.com/index.php?rid=4922078&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21655475%26dopt%3DAbstract</link>
            <description>Authors: Hegedûs Z, Barbai T, Tátrai P, Hegedûs B, Kiss A, Rásó E, Bodoky G
    Anti-angiogenic therapy became a standard care of advanced colorectal cancer. Since the most frequent genetic alteration of colorectal cancer is KRAS mutation we have analyzed its effect on the efficacy of Avastin treatment. Since 2008 we have determined the KRAS status of 575 patients with colorectal carcinoma using a sensitive screening method and sequencing. In our database the frequency of KRAS mutation in colorectal cancer is 37% (codon 12: 31% followed by codon 13: 6%). We have examined the effect of KRAS status on the efficacy of Avastin treatment in 35 patients. Progression-free survival of KRAS mutant patients was highly similar to that of wild-type patients using log-rank test (9.2+/-5.5 months v...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4922078</comments>
            <pubDate>Tue, 07 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4922078</guid>        </item>
        <item>
            <title>[Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy.]</title>
            <link>http://www.medworm.com/index.php?rid=4922077&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21655476%26dopt%3DAbstract</link>
            <description>Authors: Moldvay J, Pápay J, Furák J, Losonczy G, Matolcsy A
    Platinum-based chemotherapies are widely used in the treatment of lung cancer. However, little is known about their effect in the expression of certain tissue biomarkers. We have studied the ERCC1 (excision repair cross-complementation group 1) expression in tissue samples of patients treated with neoadjuvant chemotherapy. Fifty lung cancer tissue blocks of 25 patients (15 males, 10 females) were studied. They included 25 bronchoscopic biopsies (14 squamous cell carcinomas and 11 adenocarcinomas) together with their corresponding surgical biopsies after neoadjuvant chemotherapy. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues to study the expression of ERCC1. Staining scores (0-300) were calc...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4922077</comments>
            <pubDate>Tue, 07 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4922077</guid>        </item>
        <item>
            <title>[Complex assessment of late side effects affecting quality of life - the &quot;Debrecen model&quot;]</title>
            <link>http://www.medworm.com/index.php?rid=4922076&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21655477%26dopt%3DAbstract</link>
            <description>In conclusion, we consider it important that the treatment plans of high-risk patients with cancer should be aimed at preserving the anticancer potential of therapy, without enhancing the frequency and severity of complications. The presented &quot;Debrecen model&quot; may help in achieving this goal and in increasing quality of life of long-term survivors of childhood cancer.
    PMID: 21655477 [PubMed - as supplied by publisher] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4922076</comments>
            <pubDate>Tue, 07 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4922076</guid>        </item>
        <item>
            <title>[Paravasation of cytostatic drugs.]</title>
            <link>http://www.medworm.com/index.php?rid=4875562&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21617786%26dopt%3DAbstract</link>
            <description>Authors: Pikó B, Puskásné Szatmári K, Bassam A, Csiffári M, Dimák S, Szabó Z, Ocsai H, Csotye J
    Paravasation of cytostatic drugs during peripheral intravenous administration is a well known complication. In the United States of America it occurs in seven percent of cases with different severity and consequences. Although methods to completely avoid this complication are still unavailable, we are able to decrease the risks by identifying the patient- and procedure-related factors. The educated patient is a good indicator of paravasation in case he or she can cooperate and call the nurse. When the patient is unable to cooperate, the risks of extravasation is higher and closer nursing surveillance is indicated. The extent of injury depends mainly on the chemical structure of the ex...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4875562</comments>
            <pubDate>Wed, 30 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4875562</guid>        </item>
        <item>
            <title>[Implementation of an extravasation protocol at the National Institute of Oncology.]</title>
            <link>http://www.medworm.com/index.php?rid=4875561&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21617787%26dopt%3DAbstract</link>
            <description>Authors: Bartal A, Mátrai Z, Rosta A, Szûcs A
    Extravasation of cytostatics occurs when an infusion containing a cytotoxic drug leaks into the surrounding perivascular and subcutaneous tissues. Incidence of cytostatic extravasation is found to be 0.1-6% according to the literature. Depending on the severity of complications, pain, loss of function in the extremities, or in extreme cases tissue necrosis necessitating an amputation may develop, drawing consequences like delay or interruption of the chemotherapy. Extent of complications is greatly influenced by the type of medication administered, general condition of the patient, and professional preparedness of staff providing the oncological health service. The protocol recently implemented in the National Institute of Oncology is a s...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4875561</comments>
            <pubDate>Wed, 30 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4875561</guid>        </item>
        <item>
            <title>[Possibilities of hypnosis and hypno-suggestions methods in oncology.]</title>
            <link>http://www.medworm.com/index.php?rid=4875560&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21617788%26dopt%3DAbstract</link>
            <description>Authors: Jakubovits E
    Fear of death, pain, or the recurrence of the illness of tumor patients can narrow their attention to a point where a spontaneous altered state of consciousness occurs. In these cases hypnosis either in formal psychotherapy or embedded into the everyday communication with the physician can effectively complement other already known medical and psychological techniques. Although numerous studies have reported the beneficial physical and mental changes induced by hypnosis, for a long time there were not enough research to affect evidence-based medicine. New studies meeting the most rigorous methodological standards, new reviews and the characteristics of hypnosis shown by neuroimaging techniques support the acceptance of this method. Hypnosis is used and studied wit...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4875560</comments>
            <pubDate>Wed, 30 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4875560</guid>        </item>
        <item>
            <title>[Aromatase inhibitors and arthralgia.]</title>
            <link>http://www.medworm.com/index.php?rid=4875559&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21617789%26dopt%3DAbstract</link>
            <description>Authors: Nagykálnai T, Landherr L, Mészáros E
    In several large adjuvant clinical trials it has been demonstrated that substitution (eventually addition) of aromatase inhibitors (AIs) provides an improved outcome of endocrine-sensitive breast cancer over tamoxifen alone. Nevertheless, arthralgia induced by the AIs is one of the most frequent side effects in hormonal therapy. It is characterized by tenosynovial changes and is more frequent in patients in clinical practice than previously appreciated in adjuvant clinical trials. AI-related arthralgia may be related to estrogen deprivation, but estrogen replacement is not an option for these women. Therefore standard painkillers, NSAIDs (COX2 inhibitors), week opioids and other interventions (vitamin D, calcium, bisphosphonates, exercis...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4875559</comments>
            <pubDate>Wed, 30 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4875559</guid>        </item>
        <item>
            <title>[Oncoplastic challenges in modern breast surgery.]</title>
            <link>http://www.medworm.com/index.php?rid=4875558&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21617790%26dopt%3DAbstract</link>
            <description>Authors: Mátrai Z, Gulyás G, Tóth L, Polgár C, Bidlek M, Szabó E, Láng I, Horváth Z, Udvarhelyi N, Kunos C, Sávolt A, Pesthy P, Kásler M
    Breast screening programs along with advances in diagnostic methods and oncologic treatment have resulted in full recovery for a decisive number of patients diagnosed with early-stage breast cancer. The results of the ultra-radical-, followed by the breast conserving era pose new opportunities and challenges for the oncologic breast surgeon. The focus of oncoplastic surgery is not only on the tumor, but also on the female patient, allowing for individualized immediate breast reconstruction with acceptable esthetic result following radical tumor exstirpation. Modern procedures differ both in concept and technique from that of traditional breas...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4875558</comments>
            <pubDate>Wed, 30 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4875558</guid>        </item>
        <item>
            <title>[Investigation of the motogenic signal in human melanoma cells.]</title>
            <link>http://www.medworm.com/index.php?rid=4875557&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21617791%26dopt%3DAbstract</link>
            <description>Authors: Kenessey I
    The components of the extracellular matrix (ECM) are more than just adhesion sites for migrating tumor cells: following enzymatic degradation of the ECM, the release of sequestrated growth factors increases, thus they become available for tumor cells. In a number of cancers dysfunction of epidermal growth factor receptor (EGFR) or hepatocyte growth factor receptor (c-Met) contribute to the malignant transformation that directly regulates cell proliferation, survival and motility. Furthermore, intracellular calcium level plays an important role in the regulation of the tyrosine kinase pathway. In our preclinical experiments, by administering heparin-derived oligosaccharides we influenced the interaction between human melanoma cells and ECM. In vitro cell migration wa...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4875557</comments>
            <pubDate>Wed, 30 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4875557</guid>        </item>
        <item>
            <title>[Assessment of annual health insurance reimbursement for oncology drugs in Hungary].</title>
            <link>http://www.medworm.com/index.php?rid=4821380&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163758%26dopt%3DAbstract</link>
            <description>Authors: Boncz I, Donkáné Verebes E, Oberfrank F, Kásler M
    The aim of our study is to analyse the health insurance reimbursement of oncology drugs in outpatient care, inpatient care and named patient system. Data were derived from the database of the National Health Insurance Fund Administration (OEP). The analysis covers data of pharmaceuticals with health insurance reimbursement between 1 January and 31 December, 2008. We performed the analysis according to the ATC group &quot;L&quot; and ICD codes C00-C99 and D00-D48. Within &quot;L&quot; ATC group, for ICD codes C00-C99 and D00-D48 the annual health insurance expenditure for outpatient and named patient drugs were 36.3 billion Hungarian Forints (HUF) (144.5 million EUR, 211.3 million USD). For drugs used in the acute inpatient care, we found 22.59 ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821380</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821380</guid>        </item>
        <item>
            <title>[Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].</title>
            <link>http://www.medworm.com/index.php?rid=4821379&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163759%26dopt%3DAbstract</link>
            <description>Authors: Losonczy G, Máthé C, Müller V, Szondy K, Moldvay J
    High-dose (75 mg/m2) cisplatin is baseline chemotherapy in lung cancer. To prevent nephrotoxicity, patients generally receive saline infusion on the day of chemotherapy prior to and following cisplatin (total of 3.5-4.0 liters during 3-4 hours). Despite these measures nephrotoxicity has remained frequent, especially among patients also suffering from cardiovascular disease or diabetes mellitus. Since 2005 several international recommendations have been formed about prevention of cisplatin nephrotoxicity. According to these recommendations: 1) renal function should not be evaluated by serum creatinine concentration; 2) evaluation of renal function should be based on calculated creatinine clearance (e.g. by the Cockcroft-Gaul...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821379</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821379</guid>        </item>
        <item>
            <title>[Non-surgical biopsy in lung cancer: a paradigm shift].</title>
            <link>http://www.medworm.com/index.php?rid=4821378&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163760%26dopt%3DAbstract</link>
            <description>Authors: Strausz J, Tímár J
    Histological subgroups of non-small cell lung cancer have different prognosis and they require different therapeutic approaches. Accordingly, there is a clinical need in this field to supplement conventional pathological diagnostics with protein and genetic biomarkers that can help to recognize patients responsive to these therapies. Methods for subgroup classification and target identification were developed using surgical samples (surgical lung tumor specimens are available only in 20% of all lung cancer cases). The majority of lung cancer patients, however, have tumors that are irresectable at the time of diagnosis. Therefore, their diagnosis is usually based on bronchoscopically removed tissue or needle biopsy samples analyzed mainly by cytology. Becau...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821378</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821378</guid>        </item>
        <item>
            <title>[The role of vitamin D in the prevention and the additional therapy of cancers].</title>
            <link>http://www.medworm.com/index.php?rid=4821377&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163761%26dopt%3DAbstract</link>
            <description>Authors: Speer G
    The active metabolite of vitamin D apart from a crucial role in maintaining mineral homeostasis and skeletal functions, has antiproliferative, apoptosis and differentiation inducing as well as immunomodulatory effects in cancer. It is well known that with increasing sunshine exposure the incidence of breast, prostate and colorectal cancer is decreasing. A number of in vitro and in vivo experiments documented the effects of vitamin D in the inhibition of the tumorigenesis. In studying the role of vitamin D in cancer, it is imperative to examine the potential pathways that control local tissue levels of vitamin D. The enzyme 24-hydroxylase converts the active vitamin D to inactive metabolite. Extra-renal production of this enzyme is observed and has been increasingly rec...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821377</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821377</guid>        </item>
        <item>
            <title>[Antidiabetic therapy--a new possibility in the complex therapy of cancer?].</title>
            <link>http://www.medworm.com/index.php?rid=4821376&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163762%26dopt%3DAbstract</link>
            <description>Authors: Bánhegyi RJ, Rus-Gal PO, Nagy AK, Martyin T, Wágner R, Varga R, Pikó B
    Nowadays the lack of exercise and improper eating habits are main characteristics of modern life style. This favors not only formation of type 2 diabetes or cardiovascular diseases, but also increaseas the incidence and prevalence of malignant tumors. Today there are many epidemiologic trials that demonstrate the connection between type 2 diabetes and formation of several malignomas. Its cause should be searched in common paths of pathologic processes. One of this is the birth of hyperinsulinsulinemia, which accompanies insulin resistance. Hyperinsulinemia of the host leads to increased glucose uptake in the highly insuline sensitive tumor cells which supports tumor growth. This makes type 2 diabetes a m...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821376</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821376</guid>        </item>
        <item>
            <title>[Triple-negative breast carcinoma--rewiev of current literature].</title>
            <link>http://www.medworm.com/index.php?rid=4821375&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163763%26dopt%3DAbstract</link>
            <description>Authors: Rubovszky G, Udvarhelyi N, Horváth Z, Láng I, Kásler M
    Breast cancer is one of the most common malignancies in women. Approximately 15% of cases belong to the triple-negative breast cancer (TNBC) group, in which no estrogen/progesterone receptors, or HER2 expression is detected. The unfavorable prognosis of this group of patients, as well as the lack of effective targeted therapy makes TNBC the subject of intensive research. In the present study, we searched PubMed for publications from January 2007 to June 2009 with the following key-words in addition to &quot;breast cancer&quot; and &quot;triple negative&quot;: &quot;epidemiology&quot; or &quot;gene-profile&quot; or &quot;predictive&quot; or &quot;prognostic&quot; or &quot;therapy&quot; or &quot;review&quot;. A total of 513 publications were identified. Relevant references were also reviewed. Beyond ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821375</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821375</guid>        </item>
        <item>
            <title>[Recent advances in the treatment of gastric cancer].</title>
            <link>http://www.medworm.com/index.php?rid=4821374&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163764%26dopt%3DAbstract</link>
            <description>Authors: Dank M
    Gastric cancer is the 9th most common malignancy in Hungary, being the 4th most frequent cause of death among all cancers. The traditional treatment approaches did not turn out to be effective against advanced gastric cancer. On the other hand, due to better understanding of the underlying molecular biology of tumors, targeted therapeutics emerge resulting in longer survival times. Dank M. Recent advances in the treatment of gastric cancer.
    PMID: 21163764 [PubMed - indexed for MEDLINE] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821374</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821374</guid>        </item>
        <item>
            <title>[Pathology background of targeted therapy; quality control in pathology].</title>
            <link>http://www.medworm.com/index.php?rid=4821373&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163765%26dopt%3DAbstract</link>
            <description>Authors: Kulka J, Szirtes I, Szász AM, Kupcsulik P, Kenessey I, Lotz G, Tímár J
    The administration of targeted therapy of gastric carcinoma is a very important recent improvement of its treatment and prognosis. The basis of the successful treatment is the excellent quality of pathology, now including HER2 testing: the use of validated methods and strict criteria. This is especially important if we consider that many gastric cancers are diagnosed in small biopsy material, in which HER2 testing is challenging. This requires standardized, validated methods and experienced pathologists. Being of diagnostic and predictive significance, high quality of both the technique and the interpretation of the test is mandatory. In order to achieve general high quality in this field, technical and ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821373</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821373</guid>        </item>
        <item>
            <title>[Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case].</title>
            <link>http://www.medworm.com/index.php?rid=4821372&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163766%26dopt%3DAbstract</link>
            <description>Authors: Deme D, Ragán M, Kalmár K, Kovács L, Varga E, Varga T, Rakonczai E
    Disseminated intravascular coagulopathy (DIC) is characterized as activation of the clotting system resulting in fibrin thrombi, gradually diminishing levels of clotting factors with increased risk of bleeding. Basically two types of DIC are distinguished: (1) chronic (compensated) - with alteration of laboratory values and (2) acute (non-compensated) - with severe clinical manifestations: bleeding, shock, acute renal failure (ARF), transient focal neurologic deficit, delirium or coma. Chronic DIC related to metastatic neoplasia is caused by pancreatic, gastric or prostatic carcinoma in most of the cases. Incidence rate of DIC is 13-30% in prostate cancer, among those only 0.4-1.65% of patients had clinical ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821372</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821372</guid>        </item>
        <item>
            <title>[Non-pegylated doxorubicin (Myocet®) as the less cardiotoxic alternative of free doxorubicin].</title>
            <link>http://www.medworm.com/index.php?rid=4821371&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163767%26dopt%3DAbstract</link>
            <description>Authors: Nagykálnai T
    Anthracyclines have probably been considered to be the most active agents for the treatment of breast cancer and some other solid tumors and hematological malignancies. However, they are associated with dose-related cardiotoxicity, which can lead to progressive myocardial damage and limits the maximal cumulative dose that can be given. This review focuses on the non-pegylated liposome-encapsulated doxorubicin (Myocet®), which has been developed to increase the therapeutic index of free doxorubicin. The encapsulation of doxorubicin within a macromolecular vector, such as a liposome (&quot;nanoparticle based drug delivery system&quot;) reduces its distribution volume, diminishing its toxicity for healthy tissues while increasing the concentration within the neoplastic tissu...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821371</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821371</guid>        </item>
        <item>
            <title>[Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].</title>
            <link>http://www.medworm.com/index.php?rid=4821370&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163768%26dopt%3DAbstract</link>
            <description>Authors: Biró K, Küronya Z
    Recent advances in understanding the fundamental biology underlying clear-cell RCC have opened the door to a series of targeted agents, such as tyrosine kinase inhibitors (TKIs) or mTOR inhibitors. These new agents have become the standard of care in managing advanced clear-cell RCC. Choice of initial medical management in patients with metastatic clear-cell RCC should be guided by randomised studies. On the evidence available, the first-line therapy in patients with good- or intermediate-risk mRCC should be either sunitinib or pazopanib, or bevacizumab plus interferon. In selected patients sorafenib is an option, as is high-dose interleukin-2 if performance status is good. In patients with poor prognosis, temsirolimus is recommended. In cytokine refractory...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821370</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821370</guid>        </item>
        <item>
            <title>[Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].</title>
            <link>http://www.medworm.com/index.php?rid=4821369&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163769%26dopt%3DAbstract</link>
            <description>Authors: Réti A
    The elevated cyclooxygenase-2 (COX-2) expression has been shown to affect the carcinogenesis and tumor progression processes, including cell proliferation, motility and angiogenesis. COX-2 is overexpressed in approximately 80% of sporadic colorectal carcinomas and COX-2 enzyme is the best defined target of non-steroidal anti-inflammatory drugs (NSAIDs). In the chemotherapy of colorectal carcinomas 5-fluorouracil (5-FU) has been the most important of the basic drugs for more than 40 years. In order to improve the effectiveness of 5-FU therapy different biological modifiers i.e. inhibitors of its catabolism or activators of anabolism have been studied recently. The rate-limiting enzyme of 5-FU catabolism is dihydropyrimidine dehydrogenase (DPD) since more than 80% of the...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821369</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821369</guid>        </item>
        <item>
            <title>[Beszámoló--European Oncological Nursing Society, Spring Convention, the Hague, 2010].</title>
            <link>http://www.medworm.com/index.php?rid=4821368&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163771%26dopt%3DAbstract</link>
            <description>Authors: Cseri Z
    The Hungarian Oncological Society, Nursing Section was represented by Zsolt Cseri and László Jávor at the Spring Convention of European Oncological Nursing Society held in 2010, The Hague (Netherland). This is a short summary of our experiences and impressions of the congress. Cseri Z. Report: European Oncological Nursing Society, Spring Convention 2010, The Hague.
    PMID: 21163771 [PubMed - indexed for MEDLINE] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821368</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821368</guid>        </item>
        <item>
            <title>[Fifth Congress of the Pharmacologic Therapy Society of Hungarian Oncologists, Székesfehérvár, May 6-7, 2010. Abstracts].</title>
            <link>http://www.medworm.com/index.php?rid=4821367&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163773%26dopt%3DAbstract</link>
            <description>Authors: 
    
    PMID: 21163773 [PubMed - indexed for MEDLINE] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821367</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821367</guid>        </item>
        <item>
            <title>[16th Conference of the Hungarian Medical Physics Society, Budapest, September 24-25, 2010. Abstracts].</title>
            <link>http://www.medworm.com/index.php?rid=4821366&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163774%26dopt%3DAbstract</link>
            <description>Authors: 
    
    PMID: 21163774 [PubMed - indexed for MEDLINE] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821366</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4821366</guid>        </item>
        <item>
            <title>---</title>
            <link>http://www.medworm.com/index.php?rid=4284949&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163757%26dopt%3DAbstract</link>
            <description>Magy Onkol. 2010 Dec 1;54(4):281-282
    Authors: Eckhardt S, Besznyák I
    
    PMID: 21163757 [PubMed - as supplied by publisher] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284949</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284949</guid>        </item>
        <item>
            <title>[Assessment of annual health insurance reimbursement of oncology drugs in Hungary.]</title>
            <link>http://www.medworm.com/index.php?rid=4284948&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163758%26dopt%3DAbstract</link>
            <description>Authors: Boncz I, Donkáné Verebes E, Oberfrank F, Kásler M
    The aim of our study is to analyse the health insurance reimbursement of oncology drugs in outpatient care, inpatient care and named patient system. Data were derived from the database of the National Health Insurance Fund Administration (OEP). The analysis covers data of pharmaceuticals with health insurance reimbursement between 1 January and 31 December, 2008. We performed the analysis according to the ATC group &quot;L&quot; and ICD codes C00-C99 and D00-D48. Within &quot;L&quot; ATC group, for ICD codes C00-C99 and D00-D48 the annual health insurance expenditure for outpatient and named patient drugs were 36.3 billion Hungarian Forints (HUF) (144.5 million EUR, 211.3 million USD). For drugs used in the acute inpatient care, we found 22.59 ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284948</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284948</guid>        </item>
        <item>
            <title>[Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer.]</title>
            <link>http://www.medworm.com/index.php?rid=4284944&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163759%26dopt%3DAbstract</link>
            <description>Authors: Losonczy G, Máthé C, Müller V, Szondy K, Moldvay J
    High-dose (75 mg/m2) cisplatin is baseline chemotherapy in lung cancer. To prevent nephrotoxicity, patients generally receive saline infusion on the day of chemotherapy prior to and following cisplatin (total of 3.5-4.0 liters during 3-4 hours). Despite these measures nephrotoxicity has remained frequent, especially among patients also suffering from cardiovascular disease or diabetes mellitus. Since 2005 several international recommendations have been formed about prevention of cisplatin nephrotoxicity. According to these recommendations: 1) renal function should not be evaluated by serum creatinine concentration; 2) evaluation of renal function should be based on calculated creatinine clearance (e.g. by the Cockcroft-Gaul...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284944</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284944</guid>        </item>
        <item>
            <title>[Non-surgical biopsy in lung cancer: a paradigm shift.]</title>
            <link>http://www.medworm.com/index.php?rid=4284924&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163760%26dopt%3DAbstract</link>
            <description>Authors: Strausz J, Tímár J
    Histological subgroups of non-small cell lung cancer have different prognosis and they require different therapeutic approaches. Accordingly, there is a clinical need in this field to supplement conventional pathological diagnostics with protein and genetic biomarkers that can help to recognize patients responsive to these therapies. Methods for subgroup classification and target identification were developed using surgical samples (surgical lung tumor specimens are available only in 20% of all lung cancer cases). The majority of lung cancer patients, however, have tumors that are irresectable at the time of diagnosis. Therefore, their diagnosis is usually based on bronchoscopically removed tissue or needle biopsy samples analyzed mainly by cytology. Becau...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284924</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284924</guid>        </item>
        <item>
            <title>[The role of vitamin D in the prevention and the additional therapy of cancers.]</title>
            <link>http://www.medworm.com/index.php?rid=4284923&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163761%26dopt%3DAbstract</link>
            <description>Authors: Speer G
    The active metabolite of vitamin D apart from a crucial role in maintaining mineral homeostasis and skeletal functions, has antiproliferative, apoptosis and differentiation inducing as well as immunomodulatory effects in cancer. It is well known that with increasing sunshine exposure the incidence of breast, prostate and colorectal cancer is decreasing. A number of in vitro and in vivo experiments documented the effects of vitamin D in the inhibition of the tumorigenesis. In studying the role of vitamin D in cancer, it is imperative to examine the potential pathways that control local tissue levels of vitamin D. The enzyme 24-hydroxylase converts the active vitamin D to inactive metabolite. Extra-renal production of this enzyme is observed and has been increasingly rec...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284923</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284923</guid>        </item>
        <item>
            <title>[Correlation between type 2 diabetes and malignant tumors - new possibilities in the complex therapy of cancers?]</title>
            <link>http://www.medworm.com/index.php?rid=4284922&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163762%26dopt%3DAbstract</link>
            <description>Authors: Bánhegyi RJ, Rus-Gal PO, Nagy AK, Martyin T, Wágner R, Varga R, Pikó B
    Nowadays the lack of exercise and improper feeding are the main characteristics of modern life style. This favors not only formation of type 2 diabetes or cardiovascular diseases, but also increaseas the incidence and prevalence of malignant tumors. Today there are many epidemiologic trials that demonstrate the connection between type 2 diabetes and formation of several malignomas. Its cause should be searched in common paths of pathologic processes. One of this is the birth of hyperinsulinsulinemia, which accompanies insulin resistance. Hyperinsulinemia of the host leads to increased glucose uptake in the highly insuline sensitive tumor cells which supports tumor growth. This makes type 2 diabetes a met...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284922</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284922</guid>        </item>
        <item>
            <title>[Triple negative breast carcinoma - rewiev of current literature.]</title>
            <link>http://www.medworm.com/index.php?rid=4284921&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163763%26dopt%3DAbstract</link>
            <description>Authors: Rubovszky G, Udvarhelyi N, Horváth Z, Láng I, Kásler M
    Breast cancer is one of the most common malignancies in women. Approximately 15% of cases belong to the triple-negative breast cancer (TNBC) group, in which no estrogen/progesterone receptors, or HER2 expression is detected. The unfavorable prognosis of this group of patients, as well as the lack of effective targeted therapy makes TNBC the subject of intensive research. In the present study, we searched PubMed for publications from January 2007 to June 2009 with the following key-words in addition to &quot;breast cancer&quot; and &quot;triple negative&quot;: &quot;epidemiology&quot; or &quot;gene-profile&quot; or &quot;predictive&quot; or &quot;prognostic&quot; or &quot;therapy&quot; or &quot;review&quot;. A total of 513 publications were identified. Relevant references were also reviewed. Beyond ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284921</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284921</guid>        </item>
        <item>
            <title>[Recent advances in the treatment of gastric cancer.]</title>
            <link>http://www.medworm.com/index.php?rid=4284920&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163764%26dopt%3DAbstract</link>
            <description>Authors: Dank M
    Gastric cancer is the 9th most common malignancy in Hungary, being the 4th most frequent cause of death among all cancers. The traditional treatment approaches did not turn out to be effective against advanced gastric cancer. On the other hand, due to better understanding of the underlying molecular biology of tumors, targeted therapeutics emerge resulting in longer survival times. Dank M. Recent advances in the treatment of gastric cancer. Hungarian Oncology 54: 337-341, 2010.
    PMID: 21163764 [PubMed - as supplied by publisher] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284920</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284920</guid>        </item>
        <item>
            <title>[Pathology background of targeted therapy; quality control in pathology.]</title>
            <link>http://www.medworm.com/index.php?rid=4284919&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163765%26dopt%3DAbstract</link>
            <description>Authors: Kulka J, Szirtes I, Szász AM, Kupcsulik P, Kenessey I, Lotz G, Tímár J
    The administration of targeted therapy of gastric carcinoma is a very important recent improvement of its treatment and prognosis. The basis of the successful treatment is the excellent quality of pathology, now including HER2 testing: the use of validated methods and strict criteria. This is especially important if we consider that many gastric cancers are diagnosed in small biopsy material, in which HER2 testing is challenging. This requires standardized, validated methods and experienced pathologists. Being of diagnostic and predictive significance, high quality of both the technique and the interpretation of the test is mandatory. In order to achieve general high quality in this field, technical and ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284919</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284919</guid>        </item>
        <item>
            <title>[Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case.]</title>
            <link>http://www.medworm.com/index.php?rid=4284918&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163766%26dopt%3DAbstract</link>
            <description>Authors: Deme D, Ragán M, Kalmár K, Kovács L, Varga E, Varga T, Rakonczai E
    Disseminated intravascular coagulopathy (DIC) is characterized as activation of the clotting system resulting in fibrin thrombi, gradually diminishing levels of clotting factors with increased risk of bleeding. Basically two types of DIC are distinguished: (1) chronic (compensated) - with alteration of laboratory values and (2) acute (non-compensated) - with severe clinical manifestations: bleeding, shock, acute renal failure (ARF), transient focal neurologic deficit, delirium or coma. Chronic DIC related to metastatic neoplasia is caused by pancreatic, gastric or prostatic carcinoma in most of the cases. Incidence rate of DIC is 13-30% in prostate cancer, among those only 0.4-1.65% of patients had clinical ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284918</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284918</guid>        </item>
        <item>
            <title>[Non-pegylated doxorubicin (Myocet®) as the less cardiotoxic alternative of free doxorubicin.]</title>
            <link>http://www.medworm.com/index.php?rid=4284917&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163767%26dopt%3DAbstract</link>
            <description>Authors: Nagykálnai T
    Anthracyclines have probably been considered to be the most active agents for the treatment of breast cancer and some other solid tumors and hematological malignancies. However, they are associated with dose-related cardiotoxicity, which can lead to progressive myocardial damage and limits the maximal cumulative dose that can be given. This review focuses on the non-pegylated liposome-encapsulated doxorubicin (Myocet®), which has been developed to increase the therapeutic index of free doxorubicin. The encapsulation of doxorubicin within a macromolecular vector, such as a liposome (&quot;nanoparticle based drug delivery system&quot;) reduces its distribution volume, diminishing its toxicity for healthy tissues while increasing the concentration within the neoplastic tissu...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284917</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284917</guid>        </item>
        <item>
            <title>[Recent advancements in the treatment of renal cell carcinoma - focus on international guidelines.]</title>
            <link>http://www.medworm.com/index.php?rid=4284916&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163768%26dopt%3DAbstract</link>
            <description>Authors: Biró K, Küronya Z
    Recent advances in understanding the fundamental biology underlying clear-cell RCC have opened the door to a series of targeted agents, such as tyrosine kinase inhibitors (TKIs) or mTOR inhibitors. These new agents have become the standard of care in managing advanced clear-cell RCC. Choice of initial medical management in patients with metastatic clear-cell RCC should be guided by randomised studies. On the evidence available, the first-line therapy in patients with good- or intermediate-risk mRCC should be either sunitinib or pazopanib, or bevacizumab plus interferon. In selected patients sorafenib is an option, as is high-dose interleukin-2 if performance status is good. In patients with poor prognosis, temsirolimus is recommended. In cytokine refractory...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284916</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284916</guid>        </item>
        <item>
            <title>[Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems.]</title>
            <link>http://www.medworm.com/index.php?rid=4284915&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163769%26dopt%3DAbstract</link>
            <description>Authors: Réti A
    The elevated cyclooxygenase-2 (COX-2) expression has been shown to affect the carcinogenesis and tumor progression processes, including cell proliferation, motility and angiogenesis. COX-2 is overexpressed in approximately 80% of sporadic colorectal carcinomas and COX-2 enzyme is the best defined target of non-steroidal anti-inflammatory drugs (NSAIDs). In the chemotherapy of colorectal carcinomas 5-fluorouracil (5-FU) has been the most important of the basic drugs for more than 40 years. In order to improve the effectiveness of 5-FU therapy different biological modifiers i.e. inhibitors of its catabolism or activators of anabolism have been studied recently. The rate-limiting enzyme of 5-FU catabolism is dihydropyrimidine dehydrogenase (DPD) since more than 80% of the...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284915</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284915</guid>        </item>
        <item>
            <title>Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.</title>
            <link>http://www.medworm.com/index.php?rid=4284914&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163770%26dopt%3DAbstract</link>
            <description>Authors: László L
    Colon cancer is the second most prevalent lethal cancer. The main cause for high mortality rate is that the prognosis for progressed metastatic colon cancer is most unfavorable. Recent data suggest that disease outcome can be further improved by the addition of targeted biological agents to the first- or second-line treatment. As a result of molecularly targeted anti-EGFR therapies (cetuximab and panitumumab) complementing chemotherapy, liver metastases can reduce in size and become operable in certain patients, which can contribute to the complete recovery of the patient. The main problem, however, is the fact that a positive response only occurs in one third of the patients, even in the case of chemotherapy combined protocol, and the side effects are considerable....</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284914</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284914</guid>        </item>
        <item>
            <title>---</title>
            <link>http://www.medworm.com/index.php?rid=4284913&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21163771%26dopt%3DAbstract</link>
            <description>Magy Onkol. 2010 Dec 1;54(4):397-398
    Authors: Cseri Z
    The Hungarian Oncological Society, Nursing Section was represented by Zsolt Cseri and László Jávor at the Spring Convention of European Oncological Nursing Society held in 2010, The Hague (Netherland). This is a short summary of our experiences and impressions of the congress. Cseri Z. Report: European Oncological Nursing Society, Spring Convention 2010, The Hague. Hungarian Oncology 54: 397-398, 2010.
    PMID: 21163771 [PubMed - as supplied by publisher] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4284913</comments>
            <pubDate>Wed, 01 Dec 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4284913</guid>        </item>
        <item>
            <title>[In Process Citation]</title>
            <link>http://www.medworm.com/index.php?rid=4014260&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20870597%26dopt%3DAbstract</link>
            <description>Authors: KÃ¡sler M
    
    PMID: 20870597 [PubMed - in process] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4014260</comments>
            <pubDate>Tue, 31 Aug 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4014260</guid>        </item>
        <item>
            <title>[Stereotaxic brain radiosurgery in Hungary 1991-2009]</title>
            <link>http://www.medworm.com/index.php?rid=3943538&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576584%26dopt%3DAbstract</link>
            <description>Authors: HorvÃ¡th A
    Stereotaxic brain radiosurgery as a non-invasive type of local treatment appeared as a therapeutic approach of intracranial lesions in the middle of the last century. Originally it was developed for treating functional disorders but with the evolution of their medication the clinical need increasingly turned to treating pathomorphological intracerebral target volumes. A review of the indication's historical changes and the installation, methods, results and perspectives of Hungarian brain radiosurgery are presented. During the above mentioned period 2565 patient have been treated in five institutes of Hungary: 52% for brain metastases, 29.5% for benignomas, 12% for arteriovenous malformations, 6% for primary malignant brain tumors and 0.5% for functional disorders...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3943538</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3943538</guid>        </item>
        <item>
            <title>[Surgical treatment of cancer at the beginning of the third millenium--based on the 2004 Krompecher Memorial Lecture of the Society of Hungarian Oncologists]</title>
            <link>http://www.medworm.com/index.php?rid=3943537&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576585%26dopt%3DAbstract</link>
            <description>Authors: Balogh A
    The author presents a historical overview of cancer surgery of the last century. At the last quarter of the century the main characteristic of this process has been the significant extension of surgical radicality. Three new surgical methods appeared and have been routinely used at the Surgical Clinic of the Szeged University School, to increase surgical radicality, to improve survival rate without impairing the postoperative quality of life. 1.) Subtotal colectomy (STC) involves an extended resection of the colon over the splenic flexure. In a period of 8 years a total of 72 STCs were performed for the treatment of large bowel obstructions or symptomatic stenosis caused by cancer of the left colon. STC offers: a) one stage treatment for colonic obstruction in emergen...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3943537</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3943537</guid>        </item>
        <item>
            <title>[Laparoscopic surgery in colorectal tumors]</title>
            <link>http://www.medworm.com/index.php?rid=3943536&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576587%26dopt%3DAbstract</link>
            <description>Authors: LÃ¡zÃ¡r G, Paszt A, Simonka Z, Rokszin R, AbrahÃ¡m S
    The minimally invasive technique, by means of the undoubted advantages of the method, has become fully accepted in the surgical treatments of the most benign and functional diseases. Today it has been proven that the laparoscopic technique is safely usable also in the surgical treatment of colorectal tumors. The authors, analyzing their own and the international experiences, present the laparoscopic surgical treatment of colorectal tumors. Seventy-four patients were treated with laparoscopic-assisted colorectal intestinal resection in the Department of Surgery of the University of Szeged between January 1, 2005 and December 31, 2008. The surgical indication was neoplastic colorectal lesion in 40 cases. The average age ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3943536</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3943536</guid>        </item>
        <item>
            <title>[Surgical treatment of liver metastasis in colorectal cancer with simultaneous liver resection]</title>
            <link>http://www.medworm.com/index.php?rid=3943535&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576588%26dopt%3DAbstract</link>
            <description>This study was conducted to compare the results of patients undergoing simultaneous liver and colorectal resection for synchronous liver metastasis and of those for whom a colorectal and liver resection was made separately. A retrospective analysis was performed on 1597 patients who underwent surgery because of colorectal cancer between January 1999 and December 2008. The results of the treatment were separately evaluated in case of the 152 patients who had liver metastasis. The proportion of the liver metastasis was 9.52%. The metastases arose in 40.8% from the rectum and in 31.8% from the sigmoid colon. It proved to be inoperable in 109 (71.7%) of the 152 patients who had liver metastasis. Simultaneous liver resection was performed because of synchronous metastasis in 14 (32.6%) cases (G...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3943535</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3943535</guid>        </item>
        <item>
            <title>[Clinical and histopathological results after the neo-adjuvant treatment of advanced rectal tumors]</title>
            <link>http://www.medworm.com/index.php?rid=3943534&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576589%26dopt%3DAbstract</link>
            <description>Authors: Varga L, Baradnay G, Hohn J, Simonka Z, HideghÃ©thy K, MarÃ¡z A, NikolÃ©nyi A, VerÃ©b B, Tiszlavicz L, NÃ©meth I, MÃ¡n E, LÃ¡zÃ¡r G
    The role of the surgical intervention is decisive in treating colorectal tumors. The neo-adjuvant radio-chemotherapy has improved the efficacy of the treatment of advanced rectum tumors. In order to decrease the size and stage of advanced rectal carcinoma and to increase the rate of resecability, we introduced neoadjuvant radio-chemotherapy. We carried out neo-adjuvant and surgical treatment in case of 67 patients with rectal adenocarcinoma (T 2-4 N 1-2 M 0 ) between June 1, 2005 and July 31, 2008. The average age of the patients was 61.2 years, the division according to sex was 44 males/23 females. Regarding the local stage of the...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3943534</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3943534</guid>        </item>
        <item>
            <title>[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer]</title>
            <link>http://www.medworm.com/index.php?rid=3943533&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576590%26dopt%3DAbstract</link>
            <description>Authors: Ostoros G, DÃ¶me B, Strausz J, TÃ­mÃ¡r J
    Major advancements have been made in the clinical management of non-small cell lung cancer (NSCLC) in the past decade. This development involved the introduction of pemetrexed and several targeted therapies (bevacizumab, erlotinib, gefitinib) in the first and second line treatments of NSCLC. Novel maintenance therapeutic strategies for NSCLC (erlotinib) and for non-squamous-NSCLC (pemetrexed, bevacizumab+erlotinib) have also been developed resulting in a significant improvement in patient's survival. These changes have modified registrations of various drugs and require continuous update of guidelines and reimbursement schemes as well. These advantages are based on refinement of differential diagnosis of NSCLC and on the developme...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3943533</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3943533</guid>        </item>
        <item>
            <title>[The role of chemotherapy in pediatric medulloblastoma]</title>
            <link>http://www.medworm.com/index.php?rid=3943532&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576591%26dopt%3DAbstract</link>
            <description>Authors: Schuler D
    Medulloblastoma is one of the most frequent brain tumors in childhood. The mortality of medulloblastoma decreased significantly during the last few decades, which was the result of the better surgical and radiotherapeutic methods and of the development of chemotherapy. The aim of this publication is the critical review of the present chemotherapeutic treatment. The new therapeutic trials based on the molecular genetic mechanism of these tumors are also mentioned.
    PMID: 20576591 [PubMed - indexed for MEDLINE] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3943532</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3943532</guid>        </item>
        <item>
            <title>[Role of hypnosis and hypno-suggestions methods in the complex therapy of tumor patients]</title>
            <link>http://www.medworm.com/index.php?rid=3943531&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576592%26dopt%3DAbstract</link>
            <description>Authors: Jakubovits E
    Besides more conventional tumor risks, depression and negative life events are significant risk factors in cancer here in Hungary, therefore oncopsychology is increasingly important. We discuss traumatizing effects of the diagnosis and invasive diagnostic and therapeutic procedures from the viewpoint of altered state of consciousness. During stress and hypnosis brain functioning is altered in a similar way, which can be seen both in the patient's symptoms and his/her physiological and neuroimaging findings. In trance state patients part from reality, they no longer communicate conventionally or maturely. Hypnosis is characterized not only by physical and mental changes, but important unique social interactions as well. These interactions affect the endocrine and i...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3943531</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3943531</guid>        </item>
        <item>
            <title>[The status of domestic PET/CT attendance in the light of the waiting list data]</title>
            <link>http://www.medworm.com/index.php?rid=3943530&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576593%26dopt%3DAbstract</link>
            <description>Authors: Galuska L, Balkay L
    The aim of the study is to demonstrate the diagnostic and geographical distribution of the domestic PET/CT examinations financed by the OEP based on the data from the waiting list of the past 4 years. The analysis of the demonstrated data can support the rational usage of PET/CT examination contingents in the domestic oncological attendance, which has growing importance. PET examinations with oncological aims have started in Debrecen more than 10 years ago. In 2005 already 1500 PET examinations have been carried out. According to the governmental regulation accepted in 2006, OEP ensures the financing of the three PET/CT centers until 2012, which means 12,000 examinations in 2012. However, the number of domestic oncological patients requiring PET/CT examinat...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3943530</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3943530</guid>        </item>
        <item>
            <title>[Correlation between microsatellite instability and morphology in colorectal cancer]</title>
            <link>http://www.medworm.com/index.php?rid=3943529&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576594%26dopt%3DAbstract</link>
            <description>Authors: Szentirmay Z, Gallai M, Serester O, Szoke J, TÃ³th E
    Microsatellite instability (MSI) influences the development and clinical course of colorectal cancers (CRCs) and induce specific morphological alterations of such neoplasms, therefore hematoxylin-eosin (H&amp;E) based histology allows to predict the microsatellite status of a given tumor. The aim of this article is to demonstrate clinicopathological features that are useful in recognition of microsatellite-stable and -unstable CRCs on routine histological examination. In the Center of Surgical and Molecular Pathology of National Institute of Oncology, from 384 CRC cases 26 hereditary non-polyposis colorectal cancers (HNPCC), 22 sporadic high-level microsatellite-instable (MSI-H) cancers and 76 microsatellite-stable (MSS) o...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3943529</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3943529</guid>        </item>
        <item>
            <title>[Adenomyosis of the common bile duct]</title>
            <link>http://www.medworm.com/index.php?rid=3943528&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576595%26dopt%3DAbstract</link>
            <description>Authors: Krutsay M
    A woman 80 years of age had diffuse adenomyosis in the wall of the choledochus, near to the papilla of Vater. The lesion caused icterus and was operated (partial pancreatoduodenectomy). Adenomyosis should be considered in the differential diagnosis of obstructive jaundice.
    PMID: 20576595 [PubMed - indexed for MEDLINE] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3943528</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3943528</guid>        </item>
        <item>
            <title>[Abstracts of the 17th Primary Prevention Forum for the &quot;Prevention of Health-Harming Addictions&quot;. 20 May 2010 Budapest, Hungary]</title>
            <link>http://www.medworm.com/index.php?rid=3943527&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576596%26dopt%3DAbstract</link>
            <description>[Abstracts of the 17th Primary Prevention Forum for the &quot;Prevention of Health-Harming Addictions&quot;. 20 May 2010 Budapest, Hungary]
    Magy Onkol. 2010 Jun;54(2):181-94
    Authors: 
    
    PMID: 20576596 [PubMed - indexed for MEDLINE] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3943527</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3943527</guid>        </item>
        <item>
            <title>[Preface.]</title>
            <link>http://www.medworm.com/index.php?rid=3702842&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576583%26dopt%3DAbstract</link>
            <description>Authors: Balogh A
    
    PMID: 20576583 [PubMed - in process] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702842</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702842</guid>        </item>
        <item>
            <title>[Stereotaxic brain radiosurgery in Hungary 1991-2009.]</title>
            <link>http://www.medworm.com/index.php?rid=3702841&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576584%26dopt%3DAbstract</link>
            <description>Authors: HorvÃ¡th A
    Stereotaxic brain radiosurgery as a non-invasive type of local treatment appeared as a therapeutic approach of intracranial lesions in the middle of the last century. Originally it was developed for treating functional disorders but with the evolution of their medication the clinical need increasingly turned to treating pathomorphological intracerebral target volumes. A review of the indication's historical changes and the installation, methods, results and perspectives of Hungarian brain radiosurgery are presented. During the above mentioned period 2565 patient have been treated in five institutes of Hungary: 52% for brain metastases, 29.5% for benignomas, 12% for arteriovenous malformations, 6% for primary malignant brain tumors and 0.5% for functional disorders...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702841</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702841</guid>        </item>
        <item>
            <title>[The stage of cancer surgery at the beginning of the third millenium.]</title>
            <link>http://www.medworm.com/index.php?rid=3702840&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576585%26dopt%3DAbstract</link>
            <description>Authors: Balogh A
    The author presents a historical overview of cancer surgery of the last century. At the last quarter of the century the main characteristic of this process has been the significant extension of surgical radicality. Three new surgical methods appeared and have been routinly used at the Surgical Clinic of the Szeged University School, to increase surgical radicality, to improve survival rate without impairing the postoperative quality of life. 1.) Subtotal colectomy (STC) involves an extended resection of the colon over the splenic flexure. In a period of 8 years a total of 72 STCs were performed for the treatment of large bowel obstructions or symptomatic stenosis caused by cancer of the left colon. STC offers: a) one stage treatment for colonic obstruction in emergenc...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702840</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702840</guid>        </item>
        <item>
            <title>[In Process Citation]</title>
            <link>http://www.medworm.com/index.php?rid=3702839&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576586%26dopt%3DAbstract</link>
            <description>Authors: LÃ¡zÃ¡r G
    
    PMID: 20576586 [PubMed - in process] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702839</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702839</guid>        </item>
        <item>
            <title>[Laparoscopic surgery in colorectal tumors.]</title>
            <link>http://www.medworm.com/index.php?rid=3702838&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576587%26dopt%3DAbstract</link>
            <description>Authors: LÃ¡zÃ¡r G, Paszt A, Simonka Z, Rokszin R, AbrahÃ¡m S
    The minimally invasive technique, by means of the undoubted advantages of the method, has become fully accepted in the surgical treatments of the most benign and functional diseases. Today it has been proven that the laparoscopic technique is safely usable also in the surgical treatment of colorectal tumors. The authors, analyzing their own and the international experiences, present the laparoscopic surgical treatment of colorectal tumors. Seventy-four patients were treated with laparoscopic-assisted colorectal intestinal resection in the Department of Surgery of the University of Szeged between January 1, 2005 and December 31, 2008. The surgical indication was neoplastic colorectal lesion in 40 cases. The average age ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702838</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702838</guid>        </item>
        <item>
            <title>[Surgical treatment of liver metastasis of colorectal cancer: the impact of simultaneous liver and colorectal resection for synchronous colorectal metastasis.]</title>
            <link>http://www.medworm.com/index.php?rid=3702834&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576588%26dopt%3DAbstract</link>
            <description>This study was conducted to compare the results of patients undergoing simultaneous liver and colorectal resection for synchronous liver metastasis and of those for whom a colorectal and liver resection was made separately. A retrospective analysis was performed on 1597 patients who underwent surgery because of colorectal cancer between January 1999 and December 2008. The results of the treatment were separately evaluated in case of the 152 patients who had liver metastasis. The proportion of the liver metastasis was 9.52%. The metastases arose in 40.8% from the rectum and in 31.8% from the sigmoid colon. It proved to be inoperable in 109 (71.7%) of the 152 patients who had liver metastasis. Simultaneous liver resection was performed because of synchronous metastasis in 14 (32.6%) cases (G...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702834</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702834</guid>        </item>
        <item>
            <title>[Clinical and histopathological results after the neo-adjuvant treatment of advanced rectal tumors.]</title>
            <link>http://www.medworm.com/index.php?rid=3702833&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576589%26dopt%3DAbstract</link>
            <description>Authors: Varga L, Baradnay G, Hohn J, Simonka Z, HideghÃ©thy K, MarÃ¡z A, NikolÃ©nyi A, VerÃ©b B, Tiszlavicz L, NÃ©meth I, MÃ¡n E, LÃ¡zÃ¡r G
    The role of the surgical intervention is decisive in treating colorectal tumors. The neo-adjuvant radio-chemotherapy has improved the efficacy of the treatment of advanced rectum tumors. In order to decrease the size and stage of advanced rectal carcinoma and to increase the rate of resecability, we introduced neoadjuvant radio-chemotherapy. We carried out neo-adjuvant and surgical treatment in case of 67 patients with rectal adenocarcinoma (T 2-4 N 1-2 M 0 ) between June 1, 2005 and July 31, 2008. The average age of the patients was 61.2 years, the division according to sex was 44 males/23 females. Regarding the local stage of the...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702833</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702833</guid>        </item>
        <item>
            <title>[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer.]</title>
            <link>http://www.medworm.com/index.php?rid=3702832&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576590%26dopt%3DAbstract</link>
            <description>Authors: Ostoros G, DÃ¶me B, Strausz J, TÃ­mÃ¡r J
    Major advancements have been made in the clinical management of non-small cell lung cancer (NSCLC) in the past decade. This development involved the introduction of pemetrexed and several targeted therapies (bevacizumab, erlotinib, gefitinib) in the first and second line treatments of NSCLC. Novel maintenance therapeutic strategies for NSCLC (erlotinib) and for non-squamous-NSCLC (pemetrexed, bevacizumab+erlotinib) have also been developed resulting in a significant improvement in patient's survival. These changes have modified registrations of various drugs and require continuous update of guidelines and reimbursement schemes as well. These advantages are based on refinement of differential diagnosis of NSCLC and on the developme...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702832</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702832</guid>        </item>
        <item>
            <title>[The chemotherapy of pediatric medulloblastoma.]</title>
            <link>http://www.medworm.com/index.php?rid=3702831&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576591%26dopt%3DAbstract</link>
            <description>Authors: Schuler D
    Medulloblastoma is one of the most frequent brain tumors in childhood. The mortality of medulloblastoma decreased significantly during the last few decades, which was the result of the better surgical and radiotherapy and to the development of chemotherapy. The aim of this publication is the critical review of the present chemotherapeutic treatment. The new therapeutic trials based on the molecular genetic mechanism of these tumors are also mentioned.
    PMID: 20576591 [PubMed - in process] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702831</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702831</guid>        </item>
        <item>
            <title>[Role of hypnosis and hypno-suggestions methods in the complex therapy of tumor patients.]</title>
            <link>http://www.medworm.com/index.php?rid=3702830&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576592%26dopt%3DAbstract</link>
            <description>Authors: Jakubovits E
    Besides more conventional tumor risks, depression and negative life events are significant risk factors in cancer here in Hungary, therefore oncopsychology is increasingly important. We discuss traumatizing effects of the diagnosis and invasive diagnostic and therapeutic procedures from the viewpoint of altered state of consciousness. During stress and hypnosis brain functioning is altered in a similar way, which can be seen both in the patient's symptoms and his/her physiological and neuroimaging findings. In trance state patients part from reality, they no longer communicate conventionally or maturely. Hypnosis is characterized not only by physical and mental changes, but important unique social interactions as well. These interactions affect the endocrine and i...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702830</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702830</guid>        </item>
        <item>
            <title>[The status of domestic PET/CT attendance in the light of the waiting list data.]</title>
            <link>http://www.medworm.com/index.php?rid=3702828&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576593%26dopt%3DAbstract</link>
            <description>Authors: Galuska L, Balkay L
    The aim of the study is to demonstrate the diagnostic and geographical distribution of the domestic PET/CT examinations financed by the OEP based on the data from the waiting list of the past 4 years. The analysis of the demonstrated data can support the rational usage of PET/CT examination contingents in the domestic oncological attendance, which has growing importance. PET examinations with oncological aims have started in Debrecen more than 10 years ago. In 2005 already 1500 PET examinations have been carried out. According to the governmental regulation accepted in 2006, OEP ensures the financing of the three PET/CT centers until 2012, which means 12,000 examinations in 2012. However, the number of domestic oncological patients requiring PET/CT examinat...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702828</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702828</guid>        </item>
        <item>
            <title>[Correlation between microsatellite instability and morphology in colorectal cancer.]</title>
            <link>http://www.medworm.com/index.php?rid=3702827&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576594%26dopt%3DAbstract</link>
            <description>Authors: Szentirmay Z, Gallai M, Serester O, Szoke J, TÃ³th E
    Microsatellite instability (MSI) influences the development and clinical course of colorectal cancers (CRCs) and induce specific morphological alterations of such neoplasms, therefore hematoxylin-eosin (H&amp;E) based histology allows to predict the microsatellite status of a given tumor. The aim of this article is to demonstrate clinicopathological features that are useful in recognition of microsatellite-stable and -unstable CRCs on routine histological examination. In the Center of Surgical and Molecular Pathology of National Institute of Oncology, from 384 CRC cases 26 hereditary non-polyposis colorectal cancers (HNPCC), 22 sporadic high-level microsatellite-instable (MSI-H) cancers and 76 microsatellite-stable (MSS) o...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702827</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702827</guid>        </item>
        <item>
            <title>[Adenomyosis of the common bile duct.]</title>
            <link>http://www.medworm.com/index.php?rid=3702826&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576595%26dopt%3DAbstract</link>
            <description>Authors: Krutsay M
    A woman 80 years of age had diffuse adenomyosis in the wall of the choledochus, near to the papilla of Vater. The lesion caused icterus and was operated (partial pancreatoduodenectomy). Adenomyosis should be considered in the differential diagnosis of obstructive jaundice.
    PMID: 20576595 [PubMed - in process] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702826</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702826</guid>        </item>
        <item>
            <title>[In Process Citation]</title>
            <link>http://www.medworm.com/index.php?rid=3702825&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20576596%26dopt%3DAbstract</link>
            <description>Authors: 
    
    PMID: 20576596 [PubMed - in process] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3702825</comments>
            <pubDate>Mon, 31 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3702825</guid>        </item>
        <item>
            <title>[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes]</title>
            <link>http://www.medworm.com/index.php?rid=3646865&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350863%26dopt%3DAbstract</link>
            <description>Authors: TamÃ¡s N, LÃ¡szlÃ³ L, Edina M
    The treatment of recurrent, progressing, metastatic breast cancer, which has previously been exposed to anthracyclines and/or taxanes is not only a major clinical challenge, but has a significant social impact too. In the absence of formal guidelines, this review has aimed to summarize the published evidence that is needed to guide clinical decision-making. Four new agents are approved for use in this setting: capecitabine, gemcitabine, ixabepilone, and nanoparticle albumin-bound paclitaxel. Nevertheless this review summarizes the results of studies with other active agents, as liposomal doxorubicin, rotation of taxanes, larotaxel, vinorelbine, and other biological agents.
    PMID: 20350863 [PubMed - indexed for MEDLINE] (Source: Magyar Onk...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3646865</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3646865</guid>        </item>
        <item>
            <title>[Comparison of breast cancer in young and old women based on clinicopathological features]</title>
            <link>http://www.medworm.com/index.php?rid=3646864&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350864%26dopt%3DAbstract</link>
            <description>Authors: SzÃ©kely B, Madaras L, SzentmÃ¡rtoni G, SzÃ¡sz AM, BaranyÃ¡k Z, Szittya L, TorgyÃ­k L, ZergÃ©nyi E, BorbÃ©nyi E, Kenessey I, Korompay A, LangmÃ¡r Z, BÃ¡nhidy F, Kulka J, Dank M
    The two far ends of the age at the diagnosis of breast cancer are the age of younger than 35, and that of older than 70. Most probably, these two groups of patients differ in many ways. The aim of our present study was to underline the fact that age at the diagnosis of breast cancer is indeed a prognostic factor. Between October 1995 and March 2009, 80 old and 51 young breast cancer patients were treated at the Department of Diagnostic Radiology and Oncotherapy, Semmelweis University, Budapest. The prognostic and predictive factors of the tumors were analysed together with the disease-...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3646864</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3646864</guid>        </item>
        <item>
            <title>[Health-economics of oncology care: changes in hospital bed capacity]</title>
            <link>http://www.medworm.com/index.php?rid=3646863&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350865%26dopt%3DAbstract</link>
            <description>Authors: Boncz I, Donka-Verebes E, Oberfrank F, KÃ¡sler M
    The aim of our study was to analyze the effect of hospital bed reforms on April 1, 2007 in Hungary, with special respect to the changes of acute care cancer beds. Data were derived from the database of the National Health Insurance Fund Administration (OEP). We identified cancer care hospital capacities (beds) with the following financial codes: code nr. 12 (oncology), code nr. 24 (radiotherapy) and code nr. 28 (hematology). We analyzed the changes of these beds before and after the reform. The total number of acute care hospital beds decreased by 25.7%, while in the field of cancer care beds we found different trends. The number of hospital beds for oncology care and hematology care decreased by 11.4% and 11.1%, respectively....</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3646863</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3646863</guid>        </item>
        <item>
            <title>[Health economics of oncology care: financial effect of performance volume limit (PVL)]</title>
            <link>http://www.medworm.com/index.php?rid=3646862&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350866%26dopt%3DAbstract</link>
            <description>Authors: Boncz I, DonkÃ¡nÃ© Verebes E, Oberfrank F, KÃ¡sler M
    The aim of our study is to analyze the effect of performance volume limit (PVL) on the performance indicators of acute oncology care, with special respect to the health insurance reimbursement not paid to health care providers. Data were derived from the nationwide administrative dataset of the National Health Insurance Fund Administration (OEP) covering the period of 2006-2008. We analyzed the effect of PVL according to medical specialities. We calculated the average annual reimbursement rate of DRG cost-weight with and without the application of PVL. The loss due to PVL was calculated both by monetary terms and as the % of annual revenue. The loss of medical specialities measured by monetary units (Hungarian forint, ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3646862</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3646862</guid>        </item>
        <item>
            <title>[Effect of lifestyle counseling given by health personnel on the changes in dietary habits of Hungarian women treated for cancer]</title>
            <link>http://www.medworm.com/index.php?rid=3646861&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350867%26dopt%3DAbstract</link>
            <description>Authors: MarÃ³ti-Nagy A, Paulik E, ThurzÃ³ L
    The aim of this study was to investigate the changes in dietary habits in women with gynecological or breast cancer, and to analyze the role of some demographic factors, type of the malignant tumor, and the role of medical staff's advice in dietary behavior change of these women, after the diagnosis of cancer. A self-administered questionnaire-based retrospective study was performed, and 155 randomly selected patients, treated for gynecological or breast cancer, were involved. A self-developed questionnaire was used to measure the socio-demographic characteristics, the circumstances of visiting the physician, therapy, present health status and lifestyle before and after the diagnosis of neoplasm. More than three-fourths of the women repo...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3646861</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3646861</guid>        </item>
        <item>
            <title>[Host defense peptides and peptidomimetics as new weapons for cancer treatment]</title>
            <link>http://www.medworm.com/index.php?rid=3646860&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350868%26dopt%3DAbstract</link>
            <description>Authors: Lapis K
    Host defence peptides (HDP) produced by almost all species of living organisms and widely recognized as antimicrobial antibiotics have also proved to be capable of killing a wide variety of cancer cells. In this respect they have many advantages over conventional cytotoxic chemotherapeutic agents. They seem to kill cancer cells by effects on plasma membranes and/or the membranes of mitochondria. They are often effective against multidrug-resistant cells. They have a broad spectrum of activity in that their killing effects are not restricted to particular kinds of cancer. Above all they commonly have few side effects in that they do not have the same detrimental effects on normal cells as they do on cancer cells. It has been demonstrated that HDP can be used as effectiv...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3646860</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3646860</guid>        </item>
        <item>
            <title>[Molecular basis of bone metastasis formation and its targeted therapy]</title>
            <link>http://www.medworm.com/index.php?rid=3646859&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350869%26dopt%3DAbstract</link>
            <description>Authors: TÃ­mÃ¡r J
    Formation of bone metastasis is a hallmark of the progression of several solid cancers, providing example for the organ specificity of the process. Bone metastasis may result in both venous and arterial dissemination. Though the molecular basis of the lytic and plastic bone metastasis formation is different, in reality these organ metastases represent a mixture of the two processes. The basis of bone metastasis formation is the activation of osteoclasts and the resulting bone resorption, initiating a vicious circle by activating the initiator cancer cell. The discovery of osteoclast-bone matrix interaction inhibitor bisphosphonates revolutionized the therapy of bone metastasis. Clarifying the molecular pathways involved in bone metastasis formation identified ost...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3646859</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3646859</guid>        </item>
        <item>
            <title>[Obituary - In memoriam.]</title>
            <link>http://www.medworm.com/index.php?rid=3429838&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350862%26dopt%3DAbstract</link>
            <description>Authors: 
    
    PMID: 20350862 [PubMed - in process] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429838</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429838</guid>        </item>
        <item>
            <title>[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes.]</title>
            <link>http://www.medworm.com/index.php?rid=3429837&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350863%26dopt%3DAbstract</link>
            <description>Authors: Nagyk&amp;#xE1;lnai T, Landherr L, M&amp;#xE9;sz&amp;#xE1;ros E
    The treatment of recurrent, progressing, metastatic breast cancer, which has previously been exposed to anthracyclines and/or taxanes is not only a major clinical challenge, but has a significant social impact too. In the absence of formal guidelines, this review aimed to summarize the published evidences that are needed to guide clinical decision-making. Four new agents are approved for use in this setting: capecitabine, gemcitabine, ixabepilone, and nanoparticle albumin-bound paclitaxel. Nevertheless this review summarizes the results of studies with other active agents, as liposomal doxorubicin, rotation of taxanes, larotaxel, vinorelbine, and biologic agents.
    PMID: 20350863 [PubMed - in process] (Source: Magyar Onkolo...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429837</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429837</guid>        </item>
        <item>
            <title>[Comparison of breast cancer in young and old women based on clinicopathological features.]</title>
            <link>http://www.medworm.com/index.php?rid=3429836&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350864%26dopt%3DAbstract</link>
            <description>Authors: Sz&amp;#xE9;kely B, Madaras L, Szentm&amp;#xE1;rtoni G, Sz&amp;#xE1;sz AM, Barany&amp;#xE1;k Z, Szittya L, Torgy&amp;#xED;k L, Zerg&amp;#xE9;nyi E, Borb&amp;#xE9;nyi E, Kenessey I, Korompay A, Langm&amp;#xE1;r Z, B&amp;#xE1;nhidy F, Kulka J, Dank M
    The two far ends of the age at the diagnosis of breast cancer are the age of younger than 35, and that of older than 70. Most probably, these two groups of patients differ in many ways. The aim of our present study was to underline the fact that age at the diagnosis of breast cancer is indeed a prognostic factor. Between October 1995 and March 2009, 80 old and 51 young breast cancer patients were treated at the Department of Diagnostic Radiology and Oncotherapy, Semmelweis University, Budapest. The prognostic and predictive factors of the tumors were analysed together...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429836</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429836</guid>        </item>
        <item>
            <title>[Health-economics of oncology care: changes in hospital bed capacity.]</title>
            <link>http://www.medworm.com/index.php?rid=3429835&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350865%26dopt%3DAbstract</link>
            <description>Authors: Boncz I, Donka-Verebes E, Oberfrank F, K&amp;#xE1;sler M
    The aim of our study was to analyze the effect of hospital bed reforms on April 1, 2007 in Hungary, with special respect to the changes of acute care cancer beds. Data were derived from the database of the National Health Insurance Fund Administration (OEP). We identified cancer care hospital capacities (beds) with the following financial codes: code nr. 12 (oncology), code nr. 24 (radiotherapy) and code nr. 28 (hematology). We analyzed the changes of these beds before and after the reform. The total number of acute care hospital beds decreased by 25.7%, while in the field of cancer care beds we found different trends. The number of hospital beds for oncology care and hematology care decreased by 11.4% and 11.1%, respectivel...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429835</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429835</guid>        </item>
        <item>
            <title>[Health economics of oncology care: financial effect of performance volume limit (PVL).]</title>
            <link>http://www.medworm.com/index.php?rid=3429834&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350866%26dopt%3DAbstract</link>
            <description>Authors: Boncz I, Donka-Verebes E, Oberfrank F, K&amp;#xE1;sler M
    The aim of our study is to analyze the effect of performance volume limit (PVL) on the performance indicators of acute oncology care, with special respect to the health insurance reimbursement not paid to health care providers. Data were derived from the nationwide administrative dataset of the National Health Insurance Fund Administration (OEP) covering the period of 2006-2008. We analyzed the effect of PVL according to medical specialities. We calculated the average annual reimbursement rate of DRG cost-weight with and without the application of PVL. The loss due to PVL was calculated both by monetary terms and as the % of annual revenue. The loss of medical specialities measured by monetary units (Hungarian forint, HUF) a...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429834</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429834</guid>        </item>
        <item>
            <title>[Medical staff's advice and changes in dietary behavior in Hungarian women with cancer.]</title>
            <link>http://www.medworm.com/index.php?rid=3429833&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350867%26dopt%3DAbstract</link>
            <description>Authors: Mar&amp;#xF3;ti-Nagy A, Paulik E, Thurz&amp;#xF3; L
    The aim of this study was to investigate the changes in dietary habits in women with gynecological or breast cancer, and to analyze the role of some demographic factors, type of the malignant tumor, and the role of medical staff's advice in dietary behavior change of these women, after the diagnosis of cancer. A self-administered questionnaire-based retrospective study was performed, and 155 randomly selected patients, treated for gynecological or breast cancer, were involved. A self-developed questionnaire was used to measure the socio-demographic characteristics, the circumstances of visiting the physician, therapy, present health status and lifestyle before and after the diagnosis of neoplasm. More than three-fourths of the women ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429833</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429833</guid>        </item>
        <item>
            <title>[Host defense peptides and peptidomimetics as new weapons for cancer treatment.]</title>
            <link>http://www.medworm.com/index.php?rid=3429832&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350868%26dopt%3DAbstract</link>
            <description>Authors: Lapis K
    Host defence peptides (HDP) produced by almost all species of living organisms and widely recognized as antimicrobial antibiotics have also proved to be capable of killing a wide variety of cancer cells. In this respect they have many advantages over conventional cytotoxic chemotherapeutic agents. They seem to kill cancer cells by effects on plasma membranes and/or the membranes of mitochondria. They are often effective against multidrug-resistant cells. They have a broad spectrum of activity in that their killing effects are not restricted to particular kinds of cancer. Above all they commonly have few side effects in that they do not have the same detrimental effects on normal cells as they do on cancer cells. It has been demonstrated that HDP can be used as effectiv...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429832</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429832</guid>        </item>
        <item>
            <title>[Molecular basis of bone metastasis formation and its targeted therapy.]</title>
            <link>http://www.medworm.com/index.php?rid=3429831&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350869%26dopt%3DAbstract</link>
            <description>Authors: T&amp;#xED;m&amp;#xE1;r J
    Formation of bone metastasis is a hallmark of the progression of several solid cancers, providing example for the organ specificity of the process. Bone metastasis may result in both venous and arterial dissemination. Though the molecular basis of the lytic and plastic bone metastasis formation is different, in reality these organ metastases represent a mixture of the two processes. The basis of bone metastasis formation is the activation of osteoclasts and the resulting bone resorption, initiating a vicious circle by activating the initiator cancer cell. The discovery of osteoclast-bone matrix interaction inhibitor bisphosphonates revolutionized the therapy of bone metastasis. Clarifying the molecular pathways involved in bone metastasis formation identified...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429831</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429831</guid>        </item>
        <item>
            <title>[In Process Citation]</title>
            <link>http://www.medworm.com/index.php?rid=3429830&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20350870%26dopt%3DAbstract</link>
            <description>Authors: 
    
    PMID: 20350870 [PubMed - in process] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429830</comments>
            <pubDate>Mon, 01 Mar 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429830</guid>        </item>
        <item>
            <title>[Developments in cancer care with innovative genomics. 2008 report of the National Cancer Consortium]</title>
            <link>http://www.medworm.com/index.php?rid=3429847&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071304%26dopt%3DAbstract</link>
            <description>Authors: T&amp;#xED;m&amp;#xE1;r J, K&amp;#xE1;sler M, Heringh A, So&amp;#xF3;s M, Mathi&amp;#xE1;sz D, Rom&amp;#xE1;ny A, J&amp;#xF3;zsa A, Szil&amp;#xE1;k L, Forrai T, Patthy L, Kov&amp;#xE1;cs G
    In the 3rd year of the program 8 new molecular diagnostic services have been introduced to clinic in the management of breast-, lung-, colorectal cancers as well as in GIST and melanoma. Two patents have been filed for innovative modulation of mito/motogenic signaling pathways in cancer cells. In preclinical models of human cancer a functional imaging technique was developed to detect vascular eff ects of erythropoietin. Using a genomic approach, the sequential changes in human melanoma during systemic dissemination were determined revealing several novel potential prognostic factors and some interesting novel targets for ther...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429847</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429847</guid>        </item>
        <item>
            <title>[Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy]</title>
            <link>http://www.medworm.com/index.php?rid=3429846&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071305%26dopt%3DAbstract</link>
            <description>Authors: Kulka J, Tok&amp;#xE9;s AM, T&amp;#xF3;th AI, Sz&amp;#xE1;sz AM, Farkas A, Borka K, J&amp;#xE1;ray B, Sz&amp;#xE9;kely E, Ist&amp;#xF3;k R, Lotz G, Madaras L, Korompay A, Hars&amp;#xE1;nyi L, L&amp;#xE1;szl&amp;#xF3; Z, Rusz Z, Moln&amp;#xE1;r BA, Moln&amp;#xE1;r IA, Kenessey I, Szentm&amp;#xE1;rtoni G, Sz&amp;#xE9;kely B, Dank M
    The purpose of the study was to identify breast cancer subtypes by immunohistochemistry likely to respond to neoadjuvant chemotherapy and to analyze the used chemotherapy regimen and the range of response rates. Analysis of a collected database was performed. Ninety-two patients were identified in our files who received neoadjuvant chemotherapy between 1998 and 2009. We used immunohistochemical profiles (ER, PgR, HER2, Ki-67 and p53) of NCB, FNAB and surgical breast specimens to subclassify the tumors....</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429846</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429846</guid>        </item>
        <item>
            <title>[Neoadjuvant radiochemotherapy in the treatment of locally advanced rectal tumors]</title>
            <link>http://www.medworm.com/index.php?rid=3429845&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071306%26dopt%3DAbstract</link>
            <description>Authors: R&amp;#xE1;polti E, Szigeti A, Farkas R, Bellyei S, Boronkai A, Papp A, G&amp;#xF6;m&amp;#xF6;ri E, Horv&amp;#xE1;th OP, Mangel L
    We investigated the response rate and side effects of simultaneous, neoadjuvant radiochemotherapy (RCT) in locally advanced rectal cancer. Between 2005 and 2007, we treated 112 patients in stage II-III rectal carcinoma at the Institute of Oncotherapy, University of P&amp;#xE9;cs. For staging abdomino-pelvic CT (112) and transrectal US (49) or pelvic MR (10), or PET-CT (1) was performed. Radiation therapy was delivered with 3D CRT-based technique using belly-board with 18 MV photon energy, while patients in prone position. A total dose of 45 Gy (single dose 1.8 Gy) was delivered to the tumor and the pelvic lymph nodes. 5-FU and Ca-folinate was administered concomitantly...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429845</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429845</guid>        </item>
        <item>
            <title>[Gene expression based multigene prognostic and predictive tests in breast cancer]</title>
            <link>http://www.medworm.com/index.php?rid=3429844&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071307%26dopt%3DAbstract</link>
            <description>We present a summary of currently available RT-PCR and microarray based multigene tests including MammaPrint, Oncotype DX, BLN Assay, Theros Breast Cancer Index SM, MapQuant DX, ARUP Breast Bioclassifier, Celera Metastatic Score, eXagen BCtm, Invasive Gene Signature, Wound Response Indicator and Mammostrat. Two of these (Oncotype DX and MammaPrint) are already incorporated in several diagnostic protocols. However, multiple unsolved issues deteriorate the value of these tests: generally the validation is poor, the gene sets do not confirm each other, the associated costs are high and the necessary bioinformatics is highly complex.
    PMID: 20071307 [PubMed - indexed for MEDLINE] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429844</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429844</guid>        </item>
        <item>
            <title>[Validation study of KRAS mutation in colorectal cancer]</title>
            <link>http://www.medworm.com/index.php?rid=3429843&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071308%26dopt%3DAbstract</link>
            <description>Authors: Kopper L, T&amp;#xED;m&amp;#xE1;r J
    There is no doubt that molecular targeted therapy has increasing importance in clinical oncology. Markers related to the molecular targets can help in the prediction of the antitumoral effect as well as in the positive or negative selection of patients. Such a marker is KRAS, since its mutation inhibits the effectiveness of anti-EGFR monoclonal antibodies in the treatment of advanced and/or metastatic colorectal cancer. To identify KRAS mutations different methods and techniques are available. A voluntarily performed study served to control the validity of our methods. As a result the 7 partcipating laboratories approached but not fulfilled (except one) the criteria set by EPS. A joint discussion helped to call the attention to some technical and fi...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429843</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429843</guid>        </item>
        <item>
            <title>[Lapatinib treatment-option in trastuzumab-resistant breast cancer]</title>
            <link>http://www.medworm.com/index.php?rid=3429842&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071309%26dopt%3DAbstract</link>
            <description>Authors: Pik&amp;#xF3; B
    HER2 is overexpressed in 20-25% of breast cancers and is associated with an aggressive phenotype and poor prognosis. Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2. Having more targets, probably its antitumor activity could be more efficient. Preclinical data reveal that lapatinib has activity in trastuzumab-resistant cell lines as well as synergistic activity with trastuzumab. Phase I clinical trials have also shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common toxic effects and low incidence of cardiotoxicity. Lapatinib can cross the blood-brain barrier and might therefore have a role in preventing central-nervous-system progression. In a pivota...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429842</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429842</guid>        </item>
        <item>
            <title>[Study of claudins and prognostic factors in some gastrointestinal diseases]</title>
            <link>http://www.medworm.com/index.php?rid=3429841&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071310%26dopt%3DAbstract</link>
            <description>Authors: Gyorffy H
    Gastrointestinal tumors are highly ranked regarding tumoral mortality worldwide. The development and progression of gastrointestinal (GI) diseases go hand in hand with the changes of tight junctions (TJ). Claudins (CLDN) are the main TJ proteins, showing different expression by the different tissues, with the expressed CLDN profile being representative. I. We explored the changes of CLDN expression in Barrett's esophagus and related adenocarcinoma. CLDN2 and -3 expression in Barrett's esophagus was higher than in normal foveolar epithelium. Adenocarcinoma showed higher CLDN2 and -3 expression compared with normal and Barrett's epithelia. The similar CLDN expression profile of Barrett's esophagus and adenocarcinoma supports their sequential development. II. Gastric in...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429841</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429841</guid>        </item>
        <item>
            <title>[The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer]</title>
            <link>http://www.medworm.com/index.php?rid=3429840&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071311%26dopt%3DAbstract</link>
            <description>Authors: Szarvas T
    Bladder cancer is the second most common malignancy affecting the urinary system. Currently, histology is the only tool that determines therapy and patients' prognosis. As the treatment of non-invasive (Ta/T1) and muscle invasive (T2-T4) bladder tumors are completely different, correct staging is important, although it is often hampered by disturbing factors. Molecular methods offer new prospects for early disease detection, confirmation of unclear histological findings and prognostication. Applying molecular biological methods, the present study is searching for answers to current diagnostic and prognostic problems in bladder carcinoma. We analyzed tumor, blood and/or urine samples of 334 bladder cancer patients and 117 control individuals. Genetic alterations were ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429840</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429840</guid>        </item>
        <item>
            <title>[Prevention and therapy of bisphosphonate-induced mandibular osteonecrosis]</title>
            <link>http://www.medworm.com/index.php?rid=3429839&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071315%26dopt%3DAbstract</link>
            <description>Authors: Lajos O, Zolt&amp;#xE1;n S, Csaba H, Gyula P, L&amp;#xE1;szl&amp;#xF3; B, , , , , 
    
    PMID: 20071315 [PubMed - indexed for MEDLINE] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3429839</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3429839</guid>        </item>
        <item>
            <title>[Developments in cancer management by innovative genomics. 2008 report of the National Cancer Consortium.]</title>
            <link>http://www.medworm.com/index.php?rid=3179516&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071304%26dopt%3DAbstract</link>
            <description>Authors: T&amp;#xED;m&amp;#xE1;r J, K&amp;#xE1;sler M, Heringh A, So&amp;#xF3;s M, Mathi&amp;#xE1;sz D, Rom&amp;#xE1;ny A, J&amp;#xF3;zsa A, Szil&amp;#xE1;k L, Forrai T, Patthy L, Kov&amp;#xE1;cs G
    In the 3rd year of the program 8 new molecular diagnostic services have been introduced to clinic in the management of breast-, lung-, colorectal cancers as well as in GIST and melanoma. Two patents have been filed for innovative modulation of mito/motogenic signaling pathways in cancer cells. In preclinical models of human cancer a functional imaging technique was developed to detect vascular eff ects of erythropoietin. Using a genomic approach, the sequential changes in human melanoma during systemic dissemination were determined revealing several novel potential prognostic factors and some interesting novel targets for ther...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3179516</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3179516</guid>        </item>
        <item>
            <title>[Immunohistochemical phenotype of breast carcinomas predicts the eff ectiveness of primary systemic therapy.]</title>
            <link>http://www.medworm.com/index.php?rid=3179515&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071305%26dopt%3DAbstract</link>
            <description>Authors: Kulka J, Tok&amp;#xE9;s AM, T&amp;#xF3;th AI, Sz&amp;#xE1;sz AM, Farkas A, Borka K, J&amp;#xE1;ray B, Sz&amp;#xE9;kely E, Ist&amp;#xF3;k R, Lotz G, Madaras L, Korompay A, Hars&amp;#xE1;nyi L, L&amp;#xE1;szl&amp;#xF3; Z, Rusz Z, Moln&amp;#xE1;r BA, Moln&amp;#xE1;r IA, Kenessey I, Szentm&amp;#xE1;rtoni G, Sz&amp;#xE9;kely B, Dank M
    The purpose of the study was to identify breast cancer subtypes by immunohistochemistry likely to respond to neoadjuvant chemotherapy and to analyze the used chemotherapy regimen and the range of response rates. Analysis of a collected database was performed. Ninety-two patients were identified in our files who received neoadjuvant chemotherapy between 1998 and 2009. We used immunohistochemical profiles (ER, PgR, HER2, Ki-67 and p53) of NCB, FNAB and surgical breast specimens to subclassify the tumors....</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3179515</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3179515</guid>        </item>
        <item>
            <title>[Neoadjuvant radiochemotherapy in the treatment of locally advanced rectal tumors.]</title>
            <link>http://www.medworm.com/index.php?rid=3179514&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071306%26dopt%3DAbstract</link>
            <description>Authors: R&amp;#xE1;polti E, Szigeti A, Farkas R, Bellyei S, Boronkai A, Papp A, G&amp;#xF6;m&amp;#xF6;ri E, Horv&amp;#xE1;th OP, Mangel L
    We investigated the response rate and side effects of simultaneous, neoadjuvant radiochemotherapy (RCT) in locally advanced rectal cancer. Between 2005 and 2007, we treated 112 patients in stage II-III rectal carcinoma at the Institute of Oncotherapy, University of P&amp;#xE9;cs. For staging abdomino-pelvic CT (112) and transrectal US (49) or pelvic MR (10), or PET-CT (1) was performed. Radiation therapy was delivered with 3D CRT-based technique using belly-board with 18 MV photon energy, while patients in prone position. A total dose of 45 Gy (single dose 1.8 Gy) was delivered to the tumor and the pelvic lymph nodes. 5-FU and Ca-folinate was administered concomitantly...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3179514</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3179514</guid>        </item>
        <item>
            <title>[Gene expression based multigene prognostic and predictive tests in breast cancer.]</title>
            <link>http://www.medworm.com/index.php?rid=3179513&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071307%26dopt%3DAbstract</link>
            <description>We present a summary of currently available RT-PCR and microarray based multigene tests including MammaPrint, Oncotype DX, BLN Assay, Theros Breast Cancer Index SM, MapQuant DX, ARUP Breast Bioclassifier, Celera Metastatic Score, eXagen BCtm, Invasive Gene Signature, Wound Response Indicator and Mammostrat. Two of these (Oncotype DX and MammaPrint) are already incorporated in several diagnostic protocols. However, multiple unsolved issues deteriorate the value of these tests: generally the validation is poor, the gene sets do not confirm each other, the associated costs are high and the necessary bioinformatics is highly complex.
    PMID: 20071307 [PubMed - in process] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3179513</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3179513</guid>        </item>
        <item>
            <title>[Validation study of KRAS mutation in colorectal cancer.]</title>
            <link>http://www.medworm.com/index.php?rid=3179512&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071308%26dopt%3DAbstract</link>
            <description>Authors: Kopper L, T&amp;#xED;m&amp;#xE1;r J
    There is no doubt that molecular targeted therapy has increasing importance in clinical oncology. Markers related to the molecular targets can help in the prediction of the antitumoral effect as well as in the positive or negative selection of patients. Such a marker is KRAS, since its mutation inhibits the effectiveness of anti-EGFR monoclonal antibodies in the treatment of advanced and/or metastatic colorectal cancer. To identify KRAS mutations different methods and techniques are available. A voluntarily performed study served to control the validity of our methods. As a result the 7 partcipating laboratories approached but not fulfilled (except one) the criteria set by EPS. A joint discussion helped to call the attention to some technical and fi...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3179512</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3179512</guid>        </item>
        <item>
            <title>[Lapatinib - treatment-option in trastuzumab-resistant breast cancer.]</title>
            <link>http://www.medworm.com/index.php?rid=3179511&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071309%26dopt%3DAbstract</link>
            <description>Authors: Pik&amp;#xF3; B
    HER2 is overexpressed in 20-25% of breast cancers and is associated with an aggressive phenotype and poor prognosis. Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2. Having more targets, probably its antitumor activity could be more efficient. Preclinical data reveal that lapatinib has activity in trastuzumab-resistant cell lines as well as synergistic activity with trastuzumab. Phase I clinical trials have also shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common toxic effects and low incidence of cardiotoxicity. Lapatinib can cross the blood-brain barrier and might therefore have a role in preventing central-nervous-system progression. In a pivota...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3179511</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3179511</guid>        </item>
        <item>
            <title>[Studies on claudins and prognostic factors in gastrointestinal diseases.]</title>
            <link>http://www.medworm.com/index.php?rid=3179510&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071310%26dopt%3DAbstract</link>
            <description>Authors: Gyorffy H
    Gastrointestinal tumors are highly ranked regarding tumoral mortality worldwide. The development and progression of gastrointestinal (GI) diseases go hand in hand with the changes of tight junctions (TJ). Claudins (CLDN) are the main TJ proteins, showing different expression by the different tissues, with the expressed CLDN profile being representative. I. We explored the changes of CLDN expression in Barrett's esophagus and related adenocarcinoma. CLDN2 and -3 expression in Barrett's esophagus was higher than in normal foveolar epithelium. Adenocarcinoma showed higher CLDN2 and -3 expression compared with normal and Barrett's epithelia. The similar CLDN expression profile of Barrett's esophagus and adenocarcinoma supports their sequential development. II. Gastric in...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3179510</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3179510</guid>        </item>
        <item>
            <title>[The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer.]</title>
            <link>http://www.medworm.com/index.php?rid=3179509&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071311%26dopt%3DAbstract</link>
            <description>Authors: Szarvas T
    Bladder cancer is the second most common malignancy affecting the urinary system. Currently, histology is the only tool that determines therapy and patients' prognosis. As the treatment of non-invasive (Ta/T1) and muscle invasive (T2-T4) bladder tumors are completely different, correct staging is important, although it is often hampered by disturbing factors. Molecular methods offer new prospects for early disease detection, confirmation of unclear histological findings and prognostication. Applying molecular biological methods, the present study is searching for answers to current diagnostic and prognostic problems in bladder carcinoma. We analyzed tumor, blood and/or urine samples of 334 bladder cancer patients and 117 control individuals. Genetic alterations were ...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3179509</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3179509</guid>        </item>
        <item>
            <title>[In Process Citation]</title>
            <link>http://www.medworm.com/index.php?rid=3179508&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071312%26dopt%3DAbstract</link>
            <description>Authors: 
    
    PMID: 20071312 [PubMed - in process] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3179508</comments>
            <pubDate>Tue, 01 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3179508</guid>        </item>
        <item>
            <title>[The development of the first line treatment of metastatic colorectal cancer (mCRC)]</title>
            <link>http://www.medworm.com/index.php?rid=3172856&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19793687%26dopt%3DAbstract</link>
            <description>Authors: L&amp;#xE1;szl&amp;#xF3; L, Tam&amp;#xE1;s N
    Chemotherapy options of metastatic colorectal cancer (mCRC) have been progressed rapidly in the last years. Besides of the standard fluorouracil/folinic acid treatment some new active agents (oxaliplatin and irinotecan) have been introduced, and more recently the &quot;targeted&quot; biologicals (bevacizumab, cetuximab, panitumumab) have demonstrated their high effectiveness. This review summarizes the development of the first line treatment of mCRC.
    PMID: 19793687 [PubMed - indexed for MEDLINE] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3172856</comments>
            <pubDate>Tue, 01 Sep 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3172856</guid>        </item>
        <item>
            <title>[Quality control of computed tomography scanners from the viewpoint of radiotherapy planning in Hungary]</title>
            <link>http://www.medworm.com/index.php?rid=3172855&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19793688%26dopt%3DAbstract</link>
            <description>Authors: Csilla P, Csaba W, R&amp;#xE9;ka K, Bal&amp;#xE1;zs K, Stipan Z, Istv&amp;#xE1;n P, P&amp;#xE1;l Z
    The aim of this publication is to review the requirements necessary for using computed tomography (CT) for radiotherapy treatment planning. The equipments were tested with different CT phantoms. The authors made several measurements for checking the CT number, the quality and the mechanical parameters of CT tables. The CT numbers measured on the equipments of different manufacturers were in quite good agreement with the IAEA requirements. The geometric distortions of CT images are negligible, while the mechanical parameters of CT tables show considerable variety. A quality assurance - quality control protocol is recommended to implement in a safe workflow.
    PMID: 19793688 [PubMed - indexed fo...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3172855</comments>
            <pubDate>Tue, 01 Sep 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3172855</guid>        </item>
        <item>
            <title>[Expression pattern of invasion-related molecules in brain tumors of different origin]</title>
            <link>http://www.medworm.com/index.php?rid=3172854&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19793689%26dopt%3DAbstract</link>
            <description>In this study, the mRNA expression of 29 invasion-related molecules (18 cell membrane receptors or receptor subunits (EGFRs and integrins) and 11 ECM components: collagens, laminins and fibronectin) was investigated by quantitative reverse transcriptase-polymerase chain reaction. Fresh frozen human tissue samples from glioblastoma (GBM) and intracerebral bronchial adenocarcinoma metastases (five pieces from each) were evaluated. Significant differences were established in six of the 29 molecules (ErbB1, 2, 3, integrins alpha3, 7 and beta1). To confirm our results at the protein level, immunohistochemical analysis of nine molecules was performed. The staining intensity differed definitely in the case of ErbB1, 2 and integrins alpha3 and beta1. Determining the differences in invasion-related...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3172854</comments>
            <pubDate>Tue, 01 Sep 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3172854</guid>        </item>
        <item>
            <title>[Role of fibula in replacement of mandible]</title>
            <link>http://www.medworm.com/index.php?rid=3172853&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19793690%26dopt%3DAbstract</link>
            <description>Authors: Mikl&amp;#xF3;s F, Klara B, Mikl&amp;#xF3;s K
    The mandible and the fibula are two totally different bones of the human skeleton. The fibula is a long straight bone of the lower leg playing secondary role compared with the tibia. The mandible, or jaw bone, is the only facial bone that moves and has complex spatial structure. The blood supply of the mandible is mainly endosteal, the inferior mandibular artery, which is one of the more important branch of the maxillary artery is responsible for its arterial supply. The fibula shows the uniform pattern of periosteal blood supply receiving many small branches from the peroneal artery, and having only weak endosteal supply. The mandible articulates with the two temporal bone, and the fibula articulates with the tibia at the tibio-fibular sy...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3172853</comments>
            <pubDate>Tue, 01 Sep 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3172853</guid>        </item>
        <item>
            <title>[Metachronous metastasis from rectal adenocarcinoma to the penis--case report]</title>
            <link>http://www.medworm.com/index.php?rid=3172852&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19793691%26dopt%3DAbstract</link>
            <description>Authors: Zs&amp;#xF3;fia K, Istv&amp;#xE1;n B, J&amp;#xF3;zsef L, Vanda P, S&amp;#xE1;ndor M, Zsuzsanna P
    Despite of its rich vascularization and extensive circulatory communication with neighboring organs, penile metastases are rare. Even more infrequent is a penile metastasis of rectum tumors. Since the first report of rectal carcinoma with metastasis to the penis (Ehbert 1870), approximately 50 cases have been reported, most of them from the USA, the remaining from Western Europe, the Middle East and Japan. The first Hungarian case is reported now of penile metastasis of a rectal carcinoma. The case of a 65-year-old man is presented: isolated penile metastasis discovered 4.5 years after the primary rectal cancer resection. IHC tissue diagnosis and detailed clinical investigations confirmed metastat...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3172852</comments>
            <pubDate>Tue, 01 Sep 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3172852</guid>        </item>
        <item>
            <title>[Antitumor activity of zoledronic acid]</title>
            <link>http://www.medworm.com/index.php?rid=3172851&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19793692%26dopt%3DAbstract</link>
            <description>Authors: Lilla T
    Bisphosphonates are used for supportive treatment in bone metastases of malignant diseases. Advance in various therapeutic options, molecular targeted therapies of malignant diseases result in longer survival, and may bring a higher number of patients surviving until development of secondary lesions, e.g. bone metastases. This review summarizes the antitumor activity of the amino-bisphosphonate zoledronate, describing results of in vitro and animal model studies. Zoledronic acid treatment in patients with malignant solid tumors causing bone metastases prolongs their survival. According to the emerging, until now not too large amount of data, zoledronic acid may have a clinically significant and important direct antitumor activity which is resulted by many pathomechanic...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3172851</comments>
            <pubDate>Tue, 01 Sep 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3172851</guid>        </item>
        <item>
            <title>[Claudin expression in different pancreatic cancers and its significance in differential diagnostics]</title>
            <link>http://www.medworm.com/index.php?rid=3172850&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19793693%26dopt%3DAbstract</link>
            <description>Authors: Katalin B
    Claudins (CLDNs) are essential proteins of tight junctions. Changes in their expression pattern have been demonstrated in a number of tumors. CLDNs-3 and -4 are receptors of the Clostridium perfringens enterotoxin, cytolytic effects of the toxin are well known. The aim of our studies was to compare the different CLDN expression patterns in normal pancreas cells, pancreatic endocrine tumors, adenocarcinomas, mucinous cystic tumors and acinar cell carcinomas. Expressions of CLDN-1, -2, -3, -4 and -7 proteins were examined using immunohistochemical as well as RT-PCR techniques and the following observations were made: 1.) In addition to the well-known CLDN-1 and -4 expression CLDN-2, -3 and -7 proteins were demonstrated in ductal cells, while CLDN-3 and -7 proteins show...</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3172850</comments>
            <pubDate>Tue, 01 Sep 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3172850</guid>        </item>
        <item>
            <title>[Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients]</title>
            <link>http://www.medworm.com/index.php?rid=3172849&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19793694%26dopt%3DAbstract</link>
            <description>Authors: Krisztina B
    The aim of the research was to detect the acute and long-term ototoxic effect of cisplatin in testicular cancer patients, using OAE (otoacoustic emission), a highly sensitive new objective method, for detecting medication-related hearing loss. Secondary objective was to evaluate the risk factors that contribute to hearing loss. In the study for acute hearing loss ten males with different histological types of testicular germ cell tumor were examined with TOAE (transiently evoked otoacoustic emission), before the 1st and after the 5th day of their 1st cycle of cytostatic therapy. Patients received 100 mg/m 2 cisplatin per cycle (20 mg/m 2 for five days). Ten age-matched healthy volunteers of good hearing and without treatment were also examined with the same method....</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3172849</comments>
            <pubDate>Tue, 01 Sep 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3172849</guid>        </item>
        <item>
            <title>[Abstracts from the 16th Conference on Primary Prevention, Budapest, May 20, 2009]</title>
            <link>http://www.medworm.com/index.php?rid=3172848&amp;cid=s_33202_6_f&amp;fid=33202&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19793698%26dopt%3DAbstract</link>
            <description>Authors: 
    
    PMID: 19793698 [PubMed - indexed for MEDLINE] (Source: Magyar Onkologia)</description>
            <author>Magyar Onkologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3172848</comments>
            <pubDate>Tue, 01 Sep 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3172848</guid>        </item>
    </channel>
</rss>

